Alerta

Methods of Treating Covid-Related Disorders

Resumen de: US2025161308A1

The present disclosure relates to a method of treating long-term sequelae of infection with SARS-CoV-2, also known as long COVID. More particularly, it discloses the method of treating long COVID, the method comprising administering to a patient in need thereof a therapeutically effective amount of a HGF/MET positive modulating agent.

USE OF GAMMA PRIME FIBRINOGEN AS A BIOMARKER IN THE ASSESSMENT OF COVID-19 INFECTIONS AND PROGNOSIS OF SEVERE DISEASE

Resumen de: US2025164510A1

A method of assessing a COVID-19 infection in a person, the method comprising analysing the concentration or levels of one or more biomarkers in a biological sample from a person, wherein the one or more biomarkers comprises γ′ fibrinogen, and wherein concentration or levels of γ′ fibrinogen are elevated in a biological sample from a person infected with COVID-19 and can be used for predicting COVID-19 disease severity and/or for making a prognosis of severe COVID-19 disease in a person infected with COVID-19.

MICROWAVE DISINFECTION PROTOCOL OPTIMISED FOR THE DESTRUCTION/ INACTIVATION OF SARS-COV-2 AND H1N1 VIRUSES

Resumen de: US2025161518A1

The invention concerns a microwave disinfection device (2) configured to destroy/inactivate the SARS-COV-2 and H1N1 viruses and comprising a microwave irradiation section (22) configured to: irradiate microwave signals that have an incident electric field amplitude not higher than 6 V/m and frequencies that are included in the 8-10 GHz band and are spaced from each other by a step comprised between 10 MHZ and 100 MHz; irradiate the microwave signals at each individual frequency for a time interval comprised between 50 ms and 1 s; and irradiate the microwave signals with duty cycles comprised between 5% and 50%.

ANTIGEN BINDING MOLECULES TARGETING SARS-COV-2

Resumen de: AU2023375894A1

The disclosure provides, in various embodiments, polypeptides (e.g, antibodies and antigen binding fragments thereof) that specifically bind to receptor binding domains (RBDs) of betacoronavirus Spike glycoproteins, such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Spike glycoproteins. The disclosure also provides, in various embodiments, fusion proteins comprising one or more of polypeptides, polynucleotides encoding polypeptides, vectors and host cells suitable for expressing polypeptides, and methods for treating viral infections (e.g., COVID-19).

ATTENUATED SARS-COV-2

Resumen de: US2025161431A1

This composition of this invention is comprised of live attenuated SARS-CoV-2 constructs as vaccines or research tools. Described herein is a highly attenuated SARS-CoV-2 with deleted accessory proteins and modified transcriptional regulator sequences (TRS) that can serve as a live-attenuated vaccine platform and a BSL-2 experimental system. Certain embodiments are directed to a live attenuated SARS-CoV-2 having a modified transcriptional regulatory sequence (TRS) and a deletion of one or more open reading frames selected from ORF3a, ORF3, ORF6, ORF7, and/or ORFS.

Pharmaceutical Compositions and Methods for Treating Covid

Resumen de: US2025161262A1

Pharmaceutical compositions and methods for preventing, treating, relieving, or ameliorating symptoms of coronavirus infection, including COVID-19 and variants thereof, including treating or preventing severe illness from corona vims infection, comprising the administration of IMPDH inhibitors and/or restricted diets of guanosine-containing nucleosides or nucleotides.

Deuterium-Enriched Nirmatrelvir as SARS-CoV-2 Mpro Inhibitor for the Treatment of COVID-19

Resumen de: US2025163026A1

The present invention is concerned with novel deuterium-enriched compounds of the general chemical structural formula I., and pharmaceutically acceptable salts, compositions, and methods of use thereof,wherein, R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, R15, R16, R17, R18, R19, R20, R21, R22, R23, R24, R25 are independently D (deuterium), H (hydrogen). The compounds of general chemical formula I are novel deuterium-enriched analogs of the SARS-CoV-2 main protease (MPro) inhibitor Nirmatrelvir for the treatment of COVID-19 and related diseases caused by various coronaviruses and their variants.

FUSION PROTEIN AND USE THEREOF

Resumen de: US2025163107A1

Provided are a fusion protein and use thereof. Provided is a fusion protein, comprising a trimerization block and an immunogenic block which are connected by a linker, wherein the trimerization block comprises one or more of repeat units set forth in SEQ ID NO. 1; the immunogenic block is an immunogenic protein of a pathogen, for example, being selected from a coronavirus RBD block, an HIV membrane protein or an influenza virus hemagglutinin protein, and immunogenic fragments thereof. Compared with an immunogen monomer, the trimer can generate a higher neutralizing antibody level, does not induce a strong antibody against the trimerization block in a human body, and can promote the immune response of the organism to be focused on the immunogenic block.

INTERFERON-PRODUCING UNIVERSAL SARBECOVIRUS VACCINES, AND USES THEREOF

Resumen de: US2025161433A1

The present invention relates to universal sarbecovirus vaccines that specifically express an interferon. This live universal sarbecovirus vaccine elicits mucosal immunity and heterotypic immunity against various sarbecoviruses, including SARS-CoV-1, SARS-CoV-2, and its variants. Interferon directly encoded from the genome of the live universal sarbecovirus overrides the virus-induced “delayed type-I interferon”, resulting in enhancement of mucosal T cell responses. The present invention further relates to uses of the vaccines for the preparation of pharmaceutical compositions, methods of treating or preventing viral infections, and kits comprising the vaccines.

SARS-COV-2 NEUTRALIZING ANTIBODY

Resumen de: EP4556490A1

The present disclosure relates to a neutralizing antibody against SARS-coronavirus 2 (SARS-CoV2) or a variant virus thereof, or an antigen-binding fragment thereof. Since the neutralizing antibody of the present disclosure has inhibitory effect against SARS-coronavirus 2 and variants thereof (e.g., Delta variant, Omicron variant, etc.), it can be usefully used for prevention or treatment of infection by SARS-coronavirus 2 or variants thereof.

SARS-COV-2 VACCINE BOOSTER COMPOSITION

Resumen de: EP4556021A1

The present disclosure provides a composition for inducing or maintaining an immune response against SARS-CoV-2 virus.

HOP DERIVED COMPOUNDS FOR USE IN THE TREATMENT OF DISEASES CAUSED BY CORONAVIRUSES

Resumen de: EP4556004A1

The present invention belongs to the field of compounds for use in therapeutic treatment, and more particularly hop derived compounds for use in the treatment of diseases caused by coronaviruses.The main field of application is human health, through the development of new active beta-acid-type antivirals against SARS-CoV-2The present invention relates to hop derived compounds according to the invention for use in the treatment of diseases caused by a virus chosen from coronaviruses belonging to the Coronaviridae family.

ANTIVIRAL SULFATED CHITOSAN DERIVATIVES

Resumen de: US2025152618A1

The invention relates to sulfated chitosan derivatives of formula (I), wherein the meanings for the various substituents are as disclosed in the description, for their use in the treatment and/or prevention of a viral infection, particularly wherein the viral infection is caused by SARS-CoV-2 such as COVID-19 or RSV.

ANTIVIRAL NUCLEIC ACIDS AND COMPOSITIONS

Resumen de: AU2023366039A1

The present invention relates generally to compositions and methods for inhibiting the replication of coronaviruses and treating diseases caused by coronavirus infection. More specifically, the invention provides nucleic acids capable of inhibiting coronavirus (e.g. SARS-CoV-2) replication and their use in treating patients infected by the virus.

ANTIBODIES CAPABLE OF BINDING TO THE SPIKE PROTEIN OF CONONAVIRUS SARS-COV-2

Resumen de: US2025154231A1

The disclosure relates to antibodies useful for the prevention, treatment and/or diagnosis of coronavirus infections, and diseases and/or complications associated with coronavirus infections, including COVID-19. In particular, the disclosure relates to antibodies capable of binding to the spike protein of coronavirus SARS-CoV-2 and uses thereof.

DEVICE AND METHOD FOR PATHOGEN DETECTION

Resumen de: US2025155438A1

Systems and methods are disclosed herein for pathogen detection employing a lateral flow assay (LFA) device or ELISA assay, e.g. for detecting SARS-COV-2, the virus that causes COVID-19, in a sample. The LFA device includes a nitrocellulose membrane mounted on a solid support, a sample pad for receiving a sample, a conjugate pad containing gold nanoparticles conjugated to heavy chain antibodies (HcAbs), and an absorbent pad at the end of the device.

COMPOSITION FOR POC PCR

Resumen de: US2025155436A1

Liquid composition for the preparation of a biological sample for methods for assaying for the presence of SARS-COV-2 or genetic variations (mutant) of SARS-COV-2 wildtype in said sample by POC PCR comprising: • a) a chaotropic salt, preferably guanidinium thiocyanate, in a concentration ranging from 1 to 90 mM and • b) optionally one or more RNAse inhibitor.

NOVEL REOVIRUS-BASED VACCINE PLATFORM AND USE THEREOF

Resumen de: US2025154204A1

The present invention relates to a novel reovirus-based vaccine platform, and confirmed that a part of the S1 gene of reovirus can be replaced with various exogenous epitope-encoding genes, and a recombinant reovirus manufactured according to the present invention not only can infect target cells and induce the expression of the epitope, but also can effectively prevent and treat diseases related to the epitope by activating the immune function of immune cells against the epitope. When using the reovirus-based vaccine platform of the present invention, vaccines containing various epitopes can be manufactured through relatively simple genetic manipulation technology, and can be administered in various ways including oral administration, so it can be utilized for the prevention and treatment of various infectious diseases including SARS-CoV-2 virus infection, and cancer.

COMPOSITIONS AND METHODS FOR COVID-19 TREATMENT

Resumen de: US2025152613A1

Provided herein are compositions for use in treatment fibrosis and in treatment of COVID-19, preferably moderate COVID-19, comprising Compound (1), or a pharmaceutically acceptable salt thereof. Also provided herein are methods for treatment of COVID-19, preferably moderate COVID-19 comprising administering to a patient in need thereof an amount of between 10 mg/day and 30 mg/day, of Compound (1).

USE OF AMINOPYRIDINE, IN PARTICULAR AMIFAMPRIDINE, FOR THE TREATMENT OF A VIRALLY-ASSOCIATED FATIGUE

Resumen de: US2025152566A1

The present invention relates to a new use of an Aminopyridine, such as Pyridine-3,4-diamine, a derivative thereof and/or of a physiologically tolerable salt thereof for the prevention and/or treatment of a fatigue, which is associated with a viral infection, preferably by SARS-CoV-2. In particular for the treatment of fatigue in connection with a “post-COVID phase” and the “long COVID-19 syndrome”.

MODIFIED PRIMARY IMMUNE CELLS FOR INDUCTION OR ENHANCEMENT OF IMMUNOTHERAPY

Resumen de: US2025152710A1

Provided herein are compositions with an augmented capacity to mediate ADCC. These compositions include chimeric NK cells—called “Nukes” (NK Enhancement Strategy) that express CD64 Fc receptor from an exogenous nucleic acid molecule, the NK cells having antibodies bound thereto. Methods of using these cells for treatment of HIV, cancer, SARS-COV-2, and other diseases are provided.

NEUTRALIZING ANTIBODIES AGAINST SARS-RELATED CORONAVIRUS

Resumen de: US2025154230A1

The present invention relates to antibodies or antigen-binding fragments thereof against SARS-related coronavirus, pharmaceutical compositions comprising such antibodies or antigen-binding fragments thereof, a kit comprising such antibodies or antigen-binding fragments thereof, and the antibodies or antigen-binding fragments thereof and the pharmaceutical composition and the kit for use as a medicament, and in the treatment or prevention of a disease caused by SARS-related coronavirus.

AUTOLOGOUS CELL BASED SARS-COV-2 VACCINES

Resumen de: US2025152697A1

Disclosed herein are multi-antigenic autologous, cell-based SARS-CoV-2 vaccines comprising autologous antigen presenting cells (APCs) displaying at least two different SARS-CoV-2 antigens. These vaccines can be used to prevent SARS-CoV-2 infection or COVID-19. Further disclosed are methods for producing and using the vaccines.

CORONAVIRUS VACCINE

Resumen de: US2025152699A1

The present invention is directed to a nucleic acid suitable for use in treatment or prophylaxis of an infection with a coronavirus, preferably with a Coronavirus SARS-CoV-2, or a disorder related to such an infection, preferably COVID-19. The present invention is also directed to compositions, polypeptides, and vaccines. The compositions and vaccines preferably comprise at least one of said nucleic acid sequences, preferably nucleic acid sequences in association a lipid nanoparticle (LNP). The invention is also directed to first and second medical uses of the nucleic acid, the composition, the polypeptide, the combination, the vaccine, and the kit, and to methods of treating or preventing a coronavirus infection, preferably a Coronavirus infection.

LYOPHILIZED MRNA-LNP VACCINE PRODUCTS

Resumen de: WO2025098237A1

A lyophilized RNA-LNP (e.g., mRNA-lipid nanoparticle), a method of making or using the same, such as for vaccination using an mRNA encoding an antigenic vaccine (e.g., SARS-CoV-2).

HUMANIZED ACE2-EXPRESSING TRANSGENIC MOUSE SUSCEPTIBLE TO SARS-COV-2 VIRUS INFECTION AND METHOD FOR PRODUCING SAME

Resumen de: WO2025100882A1

The present invention discloses: a humanized ACE2-expressing transgenic mouse susceptible to SARS-CoV-2 virus infection, the mouse being obtained by applying a CRISPR system; and a method for producing same. The humanized ACE2-expressing transgenic mouse according to the present invention reflects the severity of symptoms, mortality patterns, and the like according to age, sex, viral infection dose, and the like, as observed in human COVID-19 cases, and reproduces immunopathological characteristics of SARS-CoV-2 infection in the lungs without viral replication or lesions in the brain, and thus can be effectively used to understand the pathogenesis of SARS-CoV-2 and to develop vaccines or therapeutic agents.

COMBINATION EXOSOMAL IMMUNOGENIC COMPOSITIONS AND METHODS

Resumen de: AU2023353862A1

The present disclosure relates to compositions and methods for vaccinating a subject against multiple SARS-CoV-2 variants and other respiratory viruses that involves the making and delivery of extracellular vesicles expressing on their surface engineered spike protein, engineered nucleocapsid protein, engineered hemagglutinin protein, and/or engineered respiratory syncytial virus prefusion or fusion (RSV F) protein to the subject. The present invention also relates to compositions and methods for the design, preparation, manufacture, formulation, and/or use of spike-display, nucleocapsid-display, hemagglutinin-display, and/or RSV F-display vesicular vaccines designed to elicit strong humoral and cellular immune responses against multiple respiratory viruses and variants.

NUCLEOSIDE DERIVATIVES AS ANTIVIRAL AGENTS AGAINST CORONAVIRUSES

Resumen de: WO2025098545A1

The invention relates to small molecule inhibitors of formula (I) targeting the nsp14 protein of SARS- CoV-2 and other coronaviruses, for use as antiviral agents directly targeting viral proteins.

EXTRACELLULAR VESICLE COMPOSITION FOR USE IN THE TREATMENT OF LONG COVID

Resumen de: WO2025101653A1

Long COVID or Post Acute Sequelae of COVID-19 (PASC), is a prolonged, debilitating syndrome that follows acute SARS-CoV-2 infection in >10% of cases. Human bone marrow mesenchymal stem cell derived extracellular vesicles (hBM-MSC EVs) can present a new therapeutic option.

USE OF IFN-LAMBDA MRNA FOR TREATING VIRAL INFECTIONS

Resumen de: EP4553084A2

The present invention relates to pharmaceutical compositions comprising an mRNA encoding an IFN-λ polypeptide for use in treating a viral-induced disorder, preferably a viral-induced respiratory disorder, such as COVID-19.

NUCLEOSIDE DERIVATIVES AS ANTIVIRAL AGENTS AGAINST CORONAVIRUSES

Resumen de: EP4553080A1

The invention relates to small molecule inhibitors of formula (I) targeting the nspl4 protein of SARS-CoV-2 and other coronaviruses, for use as antiviral agents directly targeting viral proteins.

SARS-CoV-2 ACE2 Transgenic mouse expressing humanized ACE2 susceptible for SARS-CoV-2 virus infection and production method therefor

Resumen de: WO2025100882A1

The present invention discloses: a humanized ACE2-expressing transgenic mouse susceptible to SARS-CoV-2 virus infection, the mouse being obtained by applying a CRISPR system; and a method for producing same. The humanized ACE2-expressing transgenic mouse according to the present invention reflects the severity of symptoms, mortality patterns, and the like according to age, sex, viral infection dose, and the like, as observed in human COVID-19 cases, and reproduces immunopathological characteristics of SARS-CoV-2 infection in the lungs without viral replication or lesions in the brain, and thus can be effectively used to understand the pathogenesis of SARS-CoV-2 and to develop vaccines or therapeutic agents.

2 A Immunoglobulin A antibody for neutralizing SARS coronavirus 2 spike antigen and uses thereof

Resumen de: KR20250064724A

본 발명은 사스 코로나바이러스 2 스파이크 항원에 특이적으로 결합하는 이뮤노글로불린 A 항체를 제조하여 이를 사스 코로나바이러스 2 검출 또는 진단 용도로 사용하거나 사스 코로나바이러스 2 중화 효과를 기반으로 사스 코로나바이러스 2 감염질환 예방 또는 치료하기 위해 사용하는 용도에 관한 것이다.

2 A Immunoglobulin A antibody for neutralizing SARS coronavirus 2 spike antigen and uses thereof

Resumen de: KR20250064725A

본 발명은 사스 코로나바이러스 2 스파이크 항원에 특이적으로 결합하는 이뮤노글로불린 A 항체를 제조하여 이를 사스 코로나바이러스 2 검출 또는 진단 용도로 사용하거나 사스 코로나바이러스 2 중화 효과를 기반으로 사스 코로나바이러스 2 감염질환 예방 또는 치료하기 위해 사용하는 용도에 관한 것이다.

BETA-CORONAVIRUS FUSION RECOMBINANT PROTEIN, AND PREPARATION METHOD AND APPLICATION THEREOF

Resumen de: US2025144062A1

Disclosed is a betacoronavirus fusion recombinant protein, comprising an RBD region and a COVID19-SF5 fragment of a spike protein of SARS-COV-2 (COVID-19), and an amino acid sequence of the COVID19-SF5 fragment is an 880th amino acid to a 1084th amino acid of the S protein of the novel coronavirus COVID-19. According to the invention, a constant conserved fragment (COVID19-SF5) and a receptor binding domain (RBD) fragment are fused and expressed to provide a more-effective constant universal vaccine candidate recombinant fusion protein for such type of coronavirus, thus providing broader and better protection measures from two standpoints of inhibiting receptor recognition and providing universal protection.

SARS-CoV-2 USE OF NOVEL POLYMER FOR PREVENTING SARS-COV-2

Resumen de: US2025134989A1

The present invention relates to a novel vaccine composition for coronavirus infection-19 comprising a polymer-based mRNA carrier. Specifically, the present invention provides a vaccine composition comprising an mRNA carrier using a novel polymer capable of delivering a negatively charged genetic material such as mRNA, and the vaccine composition has excellent effects of enhanced in vivo immune activity such as high antibody formation ability and increased interferon-gamma production.

METHODS AND DEVICES FOR RAPID DETECTION OF COVID-19 AND OTHER PATHOGENS

Resumen de: US2025144636A1

A device and method for detecting COVID-19 and other pathogens includes a sample compartment contained within an interior of the device and having multiple apertures for releasably receiving one or more test tubes containing a biological sample. A bottom portion of the test tube is contained within the interior of the device and a top portion of the test tube is exposed to atmosphere. The biological sample is lysed using the device; the lysed sample is mixed with one or more primers and then amplification (RT-LAMP) is performed using the device. A thermally conductive material on or in proximity to the sample compartment can facilitate precise heating of the compartment and sample. A thermally insulative material can be inside the interior of the housing. Multiple samples can be tested simultaneously. The results can be interpreted by a color change of the sample. The device is efficient, portable, reliable, and re-usable.

CHIMERA MOLECULES FOR SARS-COV-2 AND METHODS OF USE

Resumen de: US2025145692A1

The subject matter described herein is directed to a chimera molecule such as a polypeptide or protein chimera useful for treating or preventing a viral infection or reducing the severity, incidence, or transmissibility of a viral infection, to nucleic acid molecules encoding the polypeptide or protein chimera, and to pharmaceutical compositions containing them. Also, methods of generating such antiviral polypeptide or protein chimera, of generating nucleic acid molecules encoding the antiviral polypeptide or protein chimera, and of generating pharmaceutical compositions containing the same, and methods of using the same for treatment or prevention of a SARS-CoV-2 infection, or to reduce the severity, incidence, or transmissibility of a of a SARS-CoV-2 infection, are described.

HUMAN MONOCLONAL ANTIBODIES TARGETING THE S2 SUBUNIT OF THE SARS-COV-2 SPIKE PROTEIN

Resumen de: US2025145691A1

Provided herein are antibodies and antibody fragments that bind to the S2 subunit of the SARS-CoV-2 spike protein. Methods of treating or preventing SARS-CoV-2 infections are provided, comprising administering to a patient in need thereof an effective amount of a SARS-CoV-2 spike protein S2 subunit-targeting antibody.

HUMAN MONOCLONAL ANTIBODIES THAT BROADLY TARGET CORONAVIRUSES

Resumen de: US2025145690A1

Disclosed are monoclonal antibodies and antigen binding fragments that specifically bind a coronavirus spike protein, such as SARS-CoV-2. Also disclosed is the use of these antibodies for inhibiting a coronavirus infection. In addition, disclosed are methods for detecting a coronavirus in a biological sample, using the disclosed antibodies.

COMPOSITIONS AND METHODS FOR TREATING BIOFILMS AND NEUTROPHIL EXTRACELLULAR TRAP FORMATION

Resumen de: AU2023375471A1

Provided herein is a synthetic polypeptide derived from High Mobility Group Box 1 (HMGB 1) host protein that can both disrupt bacterial biofilms and prevent Neutrophil Extracellular Trap (NET) formation. Also provided herein are methods to disrupt aberrant or excessive NET formation that are particularly well-suited to treat high-risk populations such as those infected with SARS CoV-2, sepsis, autoimmune diseases e.g., systemic lupus erythematosus, rheumatoid arthritis, Type I diabetes mellitus, small vessel vasculitis, autoinflammatory diseases e.g., gout, inflammatory bowel disease, and metabolic diseases e.g., Type 2 diabetes and obesity.

PEPTIDE

Resumen de: US2025145667A1

The present invention relates to peptides derived from COVID-19 virus envelope protein and spike protein. The invention further relates to polynucleotides and vectors encoding said peptides, and antibodies and chimeric antigen receptors that bind to said peptides. The invention also relates to methods of diagnosis and prediction of conditions in a subject which leverage recognition of said peptides, such as by antigen-specific T cells.

COMPOSITE PARTICLE FORMULATIONS AND APPLICATIONS THEREOF

Resumen de: US2025144040A1

Composite particle including the following: (1) a nanocrystal of an organic compound, and (2) a block copolymer associated with one or more surfaces of the nanocrystal of an organic compound. The organic compound, in some embodiments, is a pharmaceutical compound, a therapeutic compound, and/or a bioactive compound. The block copolymer may be a block copolymer with at least one hydrophilic poly(2-oxazoline) block. Pharmaceutical compositions may include these composite particles. The pharmaceutical compositions may include a dispersion that has an aqueous or aqueous-based continuous phase and a dispersed phase that includes the composite particles. The dispersion may be administered to sick patients, including those diagnosed with or exhibiting symptoms of COVID-19. For example, the dispersion may be aerosolized, and a patient may inhale the aerosol.

TETANUS VACCINE PLATFORM FOR EMBEDDING COVID-19 VACCINE

Resumen de: US2025144201A1

A method of immunizing against COVID-19 by administering a recombinant SARS-CoV2 protein-based vaccine, developed by either embedding the epitopes/domains, or chemically attaching, to an already established vaccine candidate, e.g., a detoxified recombinant tetanus neurotoxin (DrTeNT). The developed vaccine will have three novel contributions compared to the present vaccine technology: a) providing a novel and very effective vaccine platform; b) priming with DrTeNT will prepare the host immune system for better response; and c) oral delivery of the vaccine candidate with a group of neurotoxin binding proteins (NAPs) from Clostridium sp. A Detoxified recombinant tetanus neurotoxin (DrTeNT) is prepared by mutation of the active site amino acid residues is an effective vaccine candidate, and is used for embedding epitopes of SARS-CoV-2 virus protein for vaccination against Covid-19. DrTeNT is a risk-free vaccine, free of formalin or any other chemical adjuvants.

COMPOSITIONS AND METHODS FOR FcRn-TARGETED INTRANASAL CORONAVIRUS VACCINATION

Resumen de: US2025144199A1

The present disclosure relates generally to novel recombinant coronavirus-based fusion proteins (“RBDs-IgG Fc protein” and “RBDs protein”) and vaccine compositions using the same, in which the fusion proteins comprise tandemly arranged coronaviruses receptor binding domains (RBDs). The present disclosure further provides methods and kits for immunizing a subject using the compositions.

USE OF VE607 FOR THE TREATMENT OF SARS-COV-2 INFECTIONS AND RELATED DISEASES

Resumen de: US2025144087A1

The present application relates to the use of 3,3′-(1,3-phenylenebis(oxy))bis(1-(piperidin-1-yl)propan-2-ol (VE607) or a pharmaceutically acceptable salt thereof for the inhibition of SARS-CoV-2 and/or management of COVID-19.

THERAPEUTIC TREATMENT FOR THE CORONAVIRUS DISEASE COVID-19

Resumen de: US2025144163A1

A therapeutic treatment for the treatment of COVID-19 disease, the treatment to be initiated soon after and preferably within approximately twenty four hours after a patient develops the first signs of symptoms comprising but not limited to individually or in combination thereof fever, headache, sore joints, cough, fatigue, chills. The treatment consists of the oral administration of an extracted component or a combination of extracted components of an herb thyme leaf also know as common thyme (Thymus Vulgaris). The treatment is thought to inhibit the replication and activity of the virus allowing the patient to regain normal health and assist in developing immunity to the virus. The treatment is not known to completely eliminate the virus from the patient therefore resulting in the patient possibly developing the same or different symptoms of the disease a second, or more times requiring additional treatments of the disclosed thyme therapeutic treatment.

ACTIVATING ENDOGENOUS ANTIMICROBIALS TO TREAT SARS-COV-2 INFECTION

Resumen de: US2025144119A1

Provided herein are methods of treating COVID-19 in a subject in need thereof, comprising administering to the subject a 25-hydroxyvitamin D compound. Also provided herein are hard capsule dosage forms of 25-hydroxyvitamin. In aspects, the 25-hydroxyvitamin D is administered as a controlled release formulation, optionally an extended release oral formulation, such as Rayaldee® extended release calcifediol capsules. Methods of treating SARS-CoV-2 infection including reducing SARS-CoV-2 viral load are provided. Methods of treating SARS-CoV-2 infection including increasing an immune response are provided.

METHOD FOR TESTING DISEASE PROGRESSION TOWARD VASCULITIS OR TESTING RISK OF COVID-19 BECOMING SEVERE, TESTING KIT, COMPANION DIAGNOSTIC AGENT, AND TESTING MARKER

Resumen de: EP4549938A1

Problem Provided are a new marker of disease activity useful for testing a diseased state of vasculitis or an exacerbation risk of COVID-19, and a means for testing a diseased state of vasculitis or an exacerbation risk of COVID-19 using the marker.Solution According to an aspect of the present invention, there are provided a method for testing a diseased state of vasculitis and a method for testing an exacerbation risk of COVID-19, the method including: detecting or quantifying, in a blood sample collected from a subject,(1) a No. 1 APOA2-like protein that causes an antigen-antibody reaction with a single chain variable region fragment consisting of an amino acid sequence set forth in SEQ ID NO: 1 and has a molecular weight of 23 to 25 kDa, and/or(2) a No. 2 APOA2-like protein that causes an antigen-antibody reaction with a single chain variable region fragment consisting of an amino acid sequence set forth in SEQ ID NO: 1 and has a molecular weight of 16 to 20 kDa.

System and method for managing diagnostic testing and results

Resumen de: GB2635230A

The present invention relates to a health and disease management system whereby a user performs a medical test on a device, whereafter the resulting test data is transmitted to an electronic database for verifying the test data and comparing the test data to benchmark data stored to derive one or more health and disease management recommendations. The device may be a self-test kit for a range of applications such as testing for COVID-19. The test data may include location data. The verification may authenticate the test results by comparing image data to an authenticity threshold value. Location data may be used to notify the user about a nearby health facility where treatment is available. A machine learning model may be trained to provide the disease management recommendations.

SELF-ASSEMBLING AMPHIPHILIC POLYMERS AS ANTI-COVID-19 AGENTS

Resumen de: MX2024000185A

There are provided improved amphiphilic comb polymers, comprising a hydrophilic backbone with regularly-spaced pendant hydrophobic moieties, having well-controlled molecular weights, structures, and end groups. The polymers self-assemble into core-corona nanoparticles in aqueous environments, which are capable of disrupting viral coat proteins, and which are capable of encapsulating antiviral drugs and prodrugs. Regularly-spaced targeting moieties optionally mediate the adherence of the nanoparticles to the viral coat. The compositions of the invention are useful as treatments for viral infection, including infections with SARS-CoV-2.

SARS-CoV-2 SARS-CoV-2 Composition For Detecting SARS-CoV-2 and Method of Detecting SARS-CoV-2 Using the Same

Resumen de: KR20250059620A

본 발명은 프라이머 쌍 및 프로브를 포함하는 신종 코로나바이러스 19(SARS-CoV-2)　검출용 조성물 및 이를 이용한 신종 코로나바이러스 19(SARS-CoV-2) 검출방법에 관한 것으로, 보다 상세하게는 재조합효소 중합효소 증폭(Recombinase Polymerase Amplification; RPA)방법을 이용한 SARS-CoV-2 검출용 조성물, 키트 및 이를 이용한 SARS-CoV-2 검출방법에 관한 것이다.

PHARMACEUTICAL COMPOSITION FOR RESISTING INFECTION WITH SARS-COV-2 OR MUTANT THEREOF, AND COMBINED DRUG THEREOF

Resumen de: EP4549452A1

Provided are a pharmaceutical composition for resisting infection with SARS-CoV-2 or a mutant thereof, and a combined drug thereof. To solve the problem of the lack of effective prevention and treatment drugs for infection with SARS-CoV-2 or a mutant virus thereof, provided are a recombinant protein vaccine and/or an adenovirus vaccine for preventing and/or treating an infection with SARS-CoV-2 or a mutant thereof, and in particular, provided are a nasal spray administration compound formulation containing active ingredients of two vaccines, i.e., a recombinant protein vaccine and an adenovirus vaccine, and a combination of the two vaccines for nasal spray administration, which can induce generation of strong antibody and cellular immune responses in vivo and block the binding of a protein S of SARS-CoV-2 to an ACE2 receptor of a host cell, thus enabling a host to resist coronavirus infection. Particularly, the present invention has good prevention and treatment effects on various mutant viruses.

ANTI-SARS-COV-2 ANTIGEN BINDING POLYPEPTIDES, POLYPEPTIDE COMPLEXES AND METHODS OF USE THEREOF

Resumen de: WO2024007013A2

Disclosed are antigen binding antigen binding polypeptide complexes (e.g., antibodies and antigen binding fragments thereof) having certain structural and/or functional features. Also disclosed are polynucleotides and vectors encoding such polypeptide complexes; host cells, pharmaceutical compositions and kits containing such polypeptide complexes; and methods of using such polypeptide complexes.

ANTI-SARS-COV-2 ANTIGEN BINDING POLYPEPTIDES, POLYPEPTIDE COMPLEXES AND METHODS OF USE THEREOF

Resumen de: AU2023301087A1

Disclosed are antigen binding polypeptides and antigen binding polypeptide complexes (e.g., antibodies and antigen binding fragments thereof) having certain structural and/or functional features. Also disclosed are polynucleotides and vectors encoding such polypeptides and polypeptide complexes; host cells, pharmaceutical compositions and kits containing such polypeptides and polypeptide complexes; and methods of using such polypeptides and polypeptide complexes.

SARS-CoV-2 Peptide set for simultaneous quantitative analysis of multiple SARS-CoV-2 subtype antigen proteins and method for analyzing antigen proteins using the peptide set

Resumen de: WO2025089473A1

The present invention provides: a peptide set for quantifying and analyzing antigen proteins of individual subtypes from a specimen containing antigen proteins of a plurality of SARS-CoV-2 subtypes; and a method for simultaneously and quantitatively analyzing antigen proteins of SARS-CoV-2 subtypes according to types thereof, using same. The peptide set comprises one or more peptides specific to individual SARS-CoV-2 subtypes, selected from the group consisting of SEQ ID NO: 1 to SEQ ID NO: 3, and a peptide common to SARS-CoV-2 subtypes, selected from SEQ ID NO: 4 or SEQ ID NO: 5.

PEPTIDE SET FOR SIMULTANEOUS QUANTITATIVE ANALYSIS OF ANTIGEN PROTEINS OF PLURALITY OF SARS-COV-2 SUBTYPES, AND ANTIGEN PROTEIN ANALYSIS METHOD USING SAME

Resumen de: WO2025089473A1

The present invention provides: a peptide set for quantifying and analyzing antigen proteins of individual subtypes from a specimen containing antigen proteins of a plurality of SARS-CoV-2 subtypes; and a method for simultaneously and quantitatively analyzing antigen proteins of SARS-CoV-2 subtypes according to types thereof, using same. The peptide set comprises one or more peptides specific to individual SARS-CoV-2 subtypes, selected from the group consisting of SEQ ID NO: 1 to SEQ ID NO: 3, and a peptide common to SARS-CoV-2 subtypes, selected from SEQ ID NO: 4 or SEQ ID NO: 5.

TEA FRACTION FOR TREATING IDIOPATHIC PULMONARY FIBROSIS

Resumen de: WO2025086933A1

The present invention provides a new tea fraction, which is made from the non-ethanol extract, and does not contain caffeine, epigallocatechin gallate (EGCG), gallic acid and catechin that are usually found in conventional tea extracts. The tea fraction has an efficacy in treating a lung fibrosis, particularly idiopathic pulmonary fibrosis (IPF), Covid-19 and long Covid.

Composition for Prevention and Treatment of Bacterial and Viral Infections and Inflammation

Resumen de: US2025134924A1

Compositions and methods for protecting against a wide spectrum of viral and bacterial infections, including Covid-19, and for treating established infection and infectious inflammation are described. The composition includes a novel combination of vitamins, minerals, nutraceuticals, and phytochemicals, which may be compounded as a pill, tablet, powder, capsule or liquid to be taken orally or via other administration routs one or more times per day, to serve as immune boosters, antibacterial agents, and antiviral agents along with providing anti-inflammatory effects in humans and animals.

COMPOSITION FOR TREATING CORONAVIRUS DISEASE 2019 (COVID-19) CONTAINING TAURODEOXYCHOLIC ACID OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND ANTIVIRAL AGENT AS ACTIVE INGREDIENTS

Resumen de: US2025134910A1

The present invention relates to a composition for treating coronavirus infection-19 (COVID-19), comprising taurodeoxycholic acid (TDCA) or a pharmaceutically acceptable salt thereof and an antiviral agent as active ingredients, it was confirmed that clinical symptoms were cured in patients with COVID-19 pneumonia who were administered a combination of a pharmaceutically acceptable salt of taurodeoxycholic acid as an inflammasome inhibitor and an antiviral agent, and thus this combination of taurodeoxycholic acid (TDCA) or a pharmaceutically acceptable salt thereof as an inflammasome inhibitor and an antiviral agent, holds promise as active ingredients in compositions for the prevention or treatment of lower respiratory tract infectious diseases, including COVID-19.

PERSISTENT SANITIZER

Resumen de: US2025134097A1

Provided herein are compositions and related methods related to a class of formulation that can be applied once a day and still provide antimicrobial and/or antiviral protection during this period, thus exhibiting persistent sanitization to the user. In some embodiments, a hand cream with antimicrobial and/or antiviral protection can prevent against COVID-19 spread or infection. In some embodiments, the formulation comprises one or more of the following: benzalkonium chloride, zinc oxide, tributyl phosphate, soybean oil, and/or Triton X-100, or an analog, derivative, salt, or pharmaceutical equivalent thereof, with the formulation containing a predominance of water to prevent a greasy feel to the user.

ANTIBODY SPECIFIC TO SPIKE PROTEIN OF SARS-COV-2 AND USES THEREOF

Resumen de: US2025136668A1

The present disclosure relates to an antibody or antigen-binding fragment thereof that specifically binds to a spike protein of SARS-CoV-2. The present disclosure also relates to a pharmaceutical composition, a method for treating and/or preventing diseases and/or disorders caused by a coronavirus in a subject in need thereof, and a method for detecting a coronavirus in a sample.

USE OF NOVEL POLYMER FOR PREVENTING SARS-COV-2

Resumen de: US2025134989A1

The present invention relates to a novel vaccine composition for coronavirus infection-19 comprising a polymer-based mRNA carrier. Specifically, the present invention provides a vaccine composition comprising an mRNA carrier using a novel polymer capable of delivering a negatively charged genetic material such as mRNA, and the vaccine composition has excellent effects of enhanced in vivo immune activity such as high antibody formation ability and increased interferon-gamma production.

MEMBRANE FUSION AND IMMUNE EVASION BY THE SPIKE PROTEIN OF SARS-COV-2 DELTA VARIANT

Resumen de: US2025134985A1

Provided herein, in some aspects, are methods for using the receptor-binidng domain (RBD) of the SARS-COV-2 S protein, including the the RBD-1, RBD-2, and/or RBD-3 regions, to identify therapeutics for the treatment of SARS-COV-2, developing a vaccine for the treatment or prevention of SARS-COV-2, and identifying a patient as being in need for a treatment for SARS-COV-2.

COMPOSITIONS AND METHODS FOR VACCINATION AGAINST PATHOGENIC CORONAVIRUS SPECIES AND VARIANTS

Resumen de: US2025134987A1

The current disclosure includes coronavirus vaccines that protect against pathogenic coronavirus species, as well as their variants. In certain embodiments, SARS-CoV-2 variant specific and multivalent coronavirus vaccines are described. The vaccines typically include a modified mRNA which encodes at least one coronavirus derived immunogen, such as a spike protein or a fragment thereof. The mRNA can be encapsulated into lipid nanoparticles or other carriers and formulated as pharmaceutical compositions which can be used to generate an immune response to coronavirus in a subject. The vaccines can be used to elicit potent B and T cell responses against SARS-CoV-2 variants and to confer protective immunity against SARS-CoV-2, as well as other pathogenic coronavirus species such as SARS-CoV and/or MERS-CoV.

COMPOSITIONS AND METHODS FOR SUPPORTING IMMUNE HEALTH

Resumen de: US2025134945A1

Various embodiments provide a method of increasing immunity to a virus in a subject. The method can comprise administering to the subject one or more effective doses of an immune-enhancing natural-based composition; thereby stimulating increased expression one or more of IFN-γ, IL-1B, IL-6, IL-10, IL-12p40, IL-12p70, and TNF-α; inhibiting replication of the virus inside a cell of the subject, and preventing entry of virus into the cell. The method of increasing immunity can further comprise increasing immunity to an upper respiratory tract viral infection. The upper respiratory tract viral infection can be COVID-19. According to some aspects of the method of increasing immunity, the effective dose of the immune-enhancing natural-based composition comprises: 30-70 mgs of cyanidin-3-glucosides; 40-80 mgs of andrographolides; 75-125 mgs of ascorbic acid; 400-600 mgs of beta glucans; 300-500 mgs of polysaccharides; and 75-125 mgs of a blend of antioxidants.

TEA FRACTION FOR TREATING IDIOPATHIC PULMONARY FIBROSIS

Resumen de: US2025134944A1

The present invention provides a new tea fraction, which is made from the non-ethanol extract, and does not contain caffeine, epigallocatechin gallate (EGCG), gallic acid and catechin that are usually found in conventional tea extracts. The tea fraction has an efficacy in treating a lung fibrosis, particularly idiopathic pulmonary fibrosis (IPF), Covid-19 and long Covid.

TRANSGENIC SEEDS FOR INHIBITING VIRAL REPLICATION VIA ANTICOMMUNICABLE FORTIFICATION SYSTEM (ACF SYSTEM) WITH CONCOMITANT METHOD OF TREATMENT OR PREVENTION OF VIRAL DISEASE, AND PANDEMIC PREVENTION AND ELIMINATION

Resumen de: US2025137007A1

Disclosed is an alternate method of prevention and treatment of diseases caused by viral pathogens of human being and animals including coronaviruses, influenza viruses, etc., by food supplementation or fortification of food with foodstuff derived from transgenic plants or parts thereof obtained from the presently disclosed transgenic plant seed. This method provides said transgenic plant seed, wherein the genome of said seed comprises an exogenous recombinant polynucleotide encoding a combination of polypeptides, which are carbohydrate binding proteins, particularly lectins that in combination as disclosed herein are combined in a manner to overcome potential toxicity caused by their transgenic expression and to lower the concentrations of each of the carbohydrate binding proteins when expressed as a part of the combination when compared to the individual transgenic expression of any of said carbohydrate binding proteins, and wherein said seed exhibit inhibition of viral replication and provide immunity against viral pathogens.

COMPOSITIONS, KITS, AND METHODS FOR DUPLEX IMMUNOASSAY FOR ANTI-SARS-COV-2 ANTIBODIES

Resumen de: US2025138011A1

Kits containing a multiplexed chemiluminescent detection system and microfluidics devices and methods for detecting the presence and/or concentration of anti-SARS-CoV-2 antibodies in a sample are disclosed. The kits, microfluidics devices, and methods utilize singlet oxygen-activatable chemiluminescent compounds in combination with two or more fluorescent molecules that emit light at different wavelengths. In certain non-limiting embodiments, the kits, microfluidics devices, and methods can distinguish between anti-SARS-CoV-2 antibodies generated in response to vaccination from anti-SARS-CoV-2 antibodies generated in response to infection.

Using Exhaled Breath Condensate for Testing for a Biomarker of COVID-19

Resumen de: US2025138004A1

An apparatus for detecting a biomarker comprises a droplet harvesting structure for converting breath vapor to a fluid droplet for forming a fluid sample and a testing system having a biomarker testing zone for receiving the fluid sample and detecting a biomarker. The droplet harvesting structure may include at least one of a hydrophobic field for receiving the breath vapor and forming the fluid droplet from the received breath vapor and hydrophilic channels for receiving the fluid droplet and channeling the fluid droplet towards the testing system. A fluid dam member may be provided disposed between the droplet harvesting structure and the biomarker testing zone.

MONOCLONAL ANTIBODIES SPECIFIC FOR FAS LIGAND AND USES THEREOF

Resumen de: AU2023372393A1

Monoclonal antibodies that specifically bind to and block the function of Fas ligand (FasL) are described. The FasL-specific antibodies can be used for the development of therapeutics for the treatment of diseases, disorders and conditions associated with the Fas/FasL signaling pathway, such as cancer, sepsis, ischemia-reperfusion injury, and coronavirus disease 2019 (COVID-19).

DIAGNOSTIC ASSAY METHODS USING ASSAY DEVICE HAVING MICROREACTOR

Resumen de: US2025138005A1

Diagnostic assay devices for detecting the presence of an analyte in a sample solution may comprise a microreactor configured to form a sample solution containing the analyte, flow the sample solution therethrough in a first direction to form an analyte-capture molecule complex, and transfer the sample solution to an absorbent strip pad configured to flow therethrough, in a second direction crossing the first direction, the sample solution including the analyte-capture molecule complex and indicate a presence of the analyte-capture molecule complex. The diagnostic devices may be used, for example, to identify the presence of SARS-Cov2, RSV, influenza A, influenza B or other pathogens in samples from patients.

NUTRACEUTICAL COMPOSITION FOR USE IN THE TREATMENT OF SUBJECTS OVER 50 WITH CHRONIC FATIGUE

Resumen de: WO2025088482A1

The present invention relates to a composition, preferably a nutraceutical composition, for use in a method of treatment of subjects over 50 suffering from chronic fatigue, particularly due to: arthritis/chronic arthritis; heart disease; post-operative convalescence; depression; diabetes; fibromyalgia; chronic rheumatic diseases; stroke; cerebral ischemia; respiratory failure; chronic respiratory disease; allergic diseases; overweight/obesity; drug use, wherein said subjects are not suffering from Long-Covid/fatigue post Covid-19 syndrome.

COMBINATION OF IAP INHIBITORS AND CELLULAR KINASE INHIBITORS, SUCH AS PONATINIB, FOR USE IN THE TREATMENT OF CANCER OR PULMONARY DISEASES, SUCH AS COPD, CYSTIC FIBROSIS, PULMONARY FIBROSIS AND COVID-19

Resumen de: WO2025090605A1

The present disclosure provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.

PHARMACOLOGICAL AGONIST OF KLF2 REDUCES OSTEOCLAST DIFFERENTIATION, INFLAMMATION, AND COVID

Resumen de: WO2025090967A1

Provided herein are compositions and methods for treating musculoskeletal disorder such as arthritis, rheumatoid arthritis, osteoporosis, wound healing, corneal epithelial dystrophies and injuries, and cytokine storm with a molecule of formula: and one or more pharmaceutical acceptable excipients or salts; and methods for preventing and/or treating musculoskeletal disorder such as arthritis, rheumatoid arthritis, osteoporosis, wound healing, corneal epithelial dystrophies and injuries, and cytokine storm triggered by a coronavirus 2 (SARS-CoV-2) infection or fibrosis in a subject.

METHOD FOR DEVELOPING OPTIMER-BASED ELECTROCHEMICAL BIOSENSOR

Resumen de: WO2025090048A1

The invention relates to an optimer-based electrochemical biosensor for use in the determination of SARS-CoV-2 S1 protein and Moxifloxacin as well as the method for its operation. The invention also includes an application of said method for the diagnosis of disease and the determination of drugs. In this context, SARS-CoV-2 S1 protein and Moxifloxacin were selected as target analytes and electrochemical analyses of these target analytes were performed using optimer-based procedure and electrochemical impedance spectroscopy technique.

ANTI-SARS-COV-2 HUMAN MONOCLONAL ANTIBODY, PHARMACEUTICAL COMPOSITION, DIAGNOSTIC KIT AND USE THEREOF

Resumen de: EP4545559A2

The present invention is part of the field of genetic engineering, more specifically, in the field of production of anti-sars-cov-2 human monoclonal antibodies. The neutralizing human antibodies of the present application can be used in the therapy of COVID19, avoiding hospitalization and aggravation of infected people with a predisposition to develop severe disease. Persons who are not infected but at risk (health and safety professionals, and others) may benefit from preventive treatment. The present invention also relates to a pharmaceutical composition comprising anti-SARS-COV-2 human monoclonal antibodies, as well as a diagnostic kit and use thereof.

CYCLOBENZAPRINE TREATMENT FOR POST-ACUTE SEQUELAE OF (SARS)-COV-2 INFECTION (PASC)

Resumen de: AU2023286504A1

The present disclosure provides methods for treating Post-Acute Sequelae of Severe Acute Respiratory Syndrome (SARS)-CoV-2 infection (PASC) or one or more symptoms associated with said PASC, comprising administering to a subject in need or at risk thereof a pharmaceutical composition comprising a therapeutically effective amount of cyclobenzaprine or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.

PEPTIDE WITH NEUTRALIZING ACTIVITY AGAINST SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2

Resumen de: EP4545970A2

The present invention relates to a peptide that specifically recognizes a protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or a portion thereof; a composition for preventing or treating SARS-CoV-2 infection, comprising the peptide; and a composition for detecting SARS-CoV-2, comprising the peptide.

PEPTIDE WITH NEUTRALIZING ACTIVITY AGAINST SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2

Resumen de: EP4545971A2

The present invention relates to a peptide that specifically recognizes a protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or a portion thereof; a composition for preventing or treating SARS-CoV-2 infection, comprising the peptide; and a composition for detecting SARS-CoV-2, comprising the peptide.

NOVEL PROTEIN AND NUCLEIC ACID SEQUENCES FOR COVID-19 VACCINES

Resumen de: ZA202311432B

The present invention relates to a mutated SARS-CoV-2 spike protein, a variant or fragment thereof or an mRNA or DNA encoding them for use in the prevention of COVID-19.

PEPTIDE WITH NEUTRALIZING ACTIVITY AGAINST SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2

Resumen de: EP4545969A2

The present invention relates to a peptide that specifically recognizes a protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or a portion thereof; a composition for preventing or treating SARS-CoV-2 infection, comprising the peptide; and a composition for detecting SARS-CoV-2, comprising the peptide.

SARS-CoV-2 Method for immobilizing epitope of SARS-CoV-2 spike protein on cell surface of lactic acid bacteria using cell surface hydrolase

Resumen de: KR20250058640A

본 발명은 세포 표면 가수분해효소를 이용하여 SARS-CoV-2 스파이크 단백질의 에피토프를 유산균의 세포 표면에 고정시키는 방법에 관한 것으로, 본 발명의 락티플랜티바실러스 플란타룸 균주 유래의 세포 표면 가수분해효소는 앵커 모티프를 가지고 있지 않음에도 불구하고, 사람에게 유익하고 안전성이 입증된 유산균의 세포 표면에 목적단백질을 고정시키는 효과가 우수하다. 따라서, 본 발명의 방법을 이용하면 백신용 항원을 간단하고 안전하게 생산할 수 있으므로, 생물공학, 치료용 단백질 의약품, 백신 등 다양한 분야에서 활용될 수 있을 것이다.

ANTIBODIES CAPABLE OF BINDING TO THE SPIKE PROTEIN OF CORONAVIRUS SARS-COV-2

Resumen de: MA61946B1

The disclosure relates to antibodies useful for the prevention, treatment and/or diagnosis of coronavirus infections, and diseases and/or complications associated with coronavirus infections, including COVID-19. In particular, the disclosure relates to antibodies capable of binding to the spike protein of coronavirus SARS-CoV-2 and uses thereof.

ANTIBODIES CAPABLE OF BINDING TO THE SPIKE PROTEIN OF CORONAVIRUS SARS-COV-2

Resumen de: MA61946B1

The disclosure relates to antibodies useful for the prevention, treatment and/or diagnosis of coronavirus infections, and diseases and/or complications associated with coronavirus infections, including COVID-19. In particular, the disclosure relates to antibodies capable of binding to the spike protein of coronavirus SARS-CoV-2 and uses thereof.

ANTIBODIES CAPABLE OF BINDING TO THE SPIKE PROTEIN OF CORONAVIRUS SARS-COV-2

Resumen de: US2024376178A1

The invention relates to antibodies useful for the prevention, treatment and/or diagnosis of coronavirus infections, and diseases and/or complications associated with coronavirus infections, including COVID-19. In particular, the invention relates to antibodies capable of binding to the spike protein of coronavirus SARS-CoV-2 and uses thereof.

A NOVEL C3D4 HUMAN CELL MODEL FOR MERS AND SARS-COV-2 INFECTION

Resumen de: WO2025085665A1

A robust human cell culture model permissive to both SARS-CoV-2 variants and MERS-CoV is critical for assessment and validation of antivirals. Human alveolar A549 cells are regarded as a valuable model for respiratory virus infection. SARS-CoV-2 uses the angiotensin converting enzyme 2 (ACE2) receptor for viral entry and the transmembrane serine protease 2 (TMPRSS2) to prime the SARS-CoV-2 spike protein. By contrast, MERS-CoV utilizes the dipeptidyl peptidase 4 receptor (DPP4) to enter the target cells. Three of which are negligibly expressed in A549. Disclosed herein is a generation of a robust human cell model that carries DPP4, ACE2, and TMPRSS2 receptor expressions. By transducing Dpp4 into A549- ACE2plusC3 cells (ACE2+/TMPRSS2+), the resulting cells expressing DPP4, ACE2 and TMPRSS2 ("ACE2plusC3D4") are highly susceptible to MERS-CoV and SARS-CoV-2 omicron infection. This ACE2plusC3D4 cell model can be applied for evaluation of antiviral drugs and potentially developed for high-throughput screening.

ANTIBODIES SPECIFIC FOR THE SPIKE PROTEIN OF SARS COV-2 CORONAVIRUS

Resumen de: WO2025083216A1

The present invention relates to antibodies capable of binding to the spike protein of coronavirus SARS-CoV-2, and methods and uses thereof in the prevention, treatment and/or diagnosis of coronavirus infections, and diseases and/or complications associated with coronavirus infections, including COVID-19.

DEVELOPMENT OF FORMULATIONS FOR THE MANAGEMENT AND ANTIVIRAL, IMMUNOMODULATORY AND ANTI-INFLAMMATORY TREATMENT OF THE NEW SARS-COV-2 INFECTION AND THE ASSOCIATED DISEASE, COVID-19, AND ITS VARIANTS, FORMULATED FROM GLYCYRRHIZIC ACID SALT AND THE DERIVATIVES THEREOF

Resumen de: WO2025084921A1

The present invention relates to the development of formulations based on the glycyrrhizic acid compound due to its antiviral, anti-inflammatory and immunomodulatory properties, as a syrup at four different concentrations of 0.1, 0.2, 1 and 2 % of the GA compound, as a solution for nebulising at four different concentrations of 0.1, 0.2, 1 and 2 % of the GA compound, and as a spray of liposomal nanoparticles at four different concentrations of 0.1, 0.2, 1 and 2 % of the GA compound. Cough suppressants, bronchospasm inhibitors and anti-corticoids are added, and lastly, the pH is adjusted in a range of 4 - 7 as this is the most physiological range. The invention is for the therapeutic and prophylactic management of infections and clinical symptoms of the infection due to SARS-CoV2 and COVID-19.

CRYSTAL FORMS OF AN ANTI-SARS COV-2 AGENT

Resumen de: AU2023356620A1

The present invention features crystalline forms of Compound I, including polymorphs and pseudopolymorphs, which are useful in the preparation of pharmaceutical compositions.

siRNA based on RNA sequence of SARS-CoV-2 and use thereof

Resumen de: US2025129368A1

The present disclosure provides siRNA that suppresses proliferation of new coronaviruses (SARS-COV-2). The siRNA disclosed herein includes: a sense strand; and an antisense strand. The sense strand includes a target sequence comprising 19 to 23 bases in which a base at a 5′ terminal is guanine (G) or cytosine (C), and an overhang comprising 2 to 4 bases added to a 3′ terminal side of the target sequence. The antisense strand includes a sequence complementary to the target sequence, and an overhang comprising 2 to 4 bases added to a 3′ terminal side of the complementary sequence. Here, at least a part of the target sequence contains at least a part of a base sequence encoding a signal peptide region of a spike protein (S protein) of SARS-COV-2.

ASSAY FOR DETECTION OF SARS-COV-2

Resumen de: US2025129438A1

A method of detecting SARS-CoV includes amplifying isothermally a target sequence in a sample with at least one set of oligonucleotide primers and assaying the sample with a SARS assay to detect the target sequence of a SARS-CoV nucleic acid sequence. A kit for detecting SARS-CoV in a sample includes a reverse transcriptase, a universal primer set suitable for loop-mediated isothermal amplification (LAMP) of the target sequence in a SARS-CoV nucleic acid sequence and variants thereof containing mutations within one or more primer binding sites.

COMPOSITIONS AND METHODS FOR TREATING CORONAVIRUS INFECTIOUS DISEASE-19 (COVID-19)

Resumen de: US2025127890A1

Compositions and methods for treating and/or diagnosing a subject having COVID-19. The treatment composition includes an inhibitor of at least one of doublecortin-like kinase 1 (DCLK1, including DCLK1 isoforms 1-4), and doublecortin-like kinase 2 (DCLK2, including DCLK2 isoforms 1-3). The treatment composition may optionally include an inhibitor of SI 00 calcium binding protein A9 (S100A9), calprotectin (S100A8/S100A9 complex), S100A4, Granulocyte-macrophage colony-stimulating factor (GM-CSF), Vascular endothelial growth factor (VEGF), Interleukin-6 (IL-6), or combinations thereof. The subject may also have a chronic liver disease, disorder, or condition. A method of determining if a patient having COVID-19 should be administered a treatment protocol for severe or critical COVID-19.

FUSION POLYPEPTIDE

Resumen de: US2025127880A1

Disclosed herein are fusion polypeptides comprising at least one peptide domain from a severe acute respiratory syndrome coronavirus (SARS CoV-2) spike protein (S-protein), polynucleotides encoding such fusion polypeptides, methods of making such polypeptides and polynucleotides, pharmaceutical compositions and vaccines comprising such polypeptides or polynucleotides, and methods of using such polypeptides and/or polynucleotides for the treatment or prevention of SARS CoV-2 infection in a subject.

An Immunogenic Composition of Disease-Associated Antigens for Use in a Vaccine, Antibody Production and Immunodiagnostic Tests

Resumen de: US2025127881A1

The invention is based on the deletion of 21 amino acids from the C-terminal region of the S2 subunit of SARS-CoV2-S protein and transporting the Si subunit, which is fused to S2 to the cell membranes. In this way, the presentation of the antigenic S1 subunit of SARS-CoV2-S protein in large amounts and in its natural structure in the cell membrane and its use as a whole cell or cell membrane has been determined as a new vaccination protocol for the SARS-CoV-2. Designing the S2 subunit of SARS-CoV2-S protein as a carrier, fusing any bacterial, viral, and tumor proteins with antigenic properties and transporting it to the cell membrane will be a comprehensive vaccination protocol that will cover all bacteria, viruses and even tumors.

BUTYROPHILIN (BTN) 3A ACTIVATING ANTIBODIES FOR USE IN METHODS FOR TREATING INFECTIOUS DISORDERS

Resumen de: US2025129165A1

The present disclosure relates to methods for treating infectious disorders. In particular, the disclosure provides BTN3A activating antibodies, and their use in treating infectious disorders in a human subject in need thereof, such as disorders caused by SARS-Cov2 or Coxiella burnetii infection.

ALZ-801 FOR USE IN TREATING A COVID-19 ASSOCIATED NEUROLOGICAL SYMPTOM

Resumen de: US2025127734A1

Provided herein are methods for reducing p-tau, Abeta40, Abeta42, and/or the p-tau/Abeta+2 ratio in subjects using ALZ-801. Also provided are methods of treating conditions associated with elevated levels of p-tau, elevated levels of Abeta40, elevated levels of Abeta42, and/or an elevated p-tau/Abeta42 ratio.

Combination therapy of omega-3, black cumin, manuka honey, Anise, Vitamin-D, Nutmeg in treating COVID-19

Resumen de: US2025127744A1

The present invention relates to treating SARS-CoV-2 infection by concurrent administration of different treatment supplementation through anti-inflammatory, antioxidant, antiviral, and immunoregulation actions. The lower doses of the proposed treatment modalities in the present invention denoted anti-inflammatory, antioxidant, antiviral, and immunoregulation actions. The higher doses of the proposed treatment modalities in the present invention promoted the release the CD4+ and CD8+ T cell, increasing the phagocytosis activity for viral clearance of SARS-CoV-2 infection. The proposed treatment modalities in the present invention allow the maturation of antibodies against natural SARS-CoV-2 infection.

METHODS, DEVICES, AND RELATED ASPECTS FOR DETECTING SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS-2

Resumen de: US2025130230A1

Provided herein are methods of detecting severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) in a sample. The methods include contacting the sample with a plurality of gold nanoparticles (AuNPs) and/or other plasmonic metal nanoparticles (MNPs) that are conjugated with at least two sets of antibodies, or antigen binding portions thereof, that binds to at least first and second epitopes of SARS-CoV-2 proteins, such as receptor-binding domain (RBDs) under conditions sufficient for the antibodies, or the antigen binding portions thereof, to bind to the first and second epitopes of the SARS-CoV-2 proteins in the sample to produce bound SARS-CoV-2 proteins. The methods also include detecting the SARS-CoV-2 proteins when aggregations of the bound SARS-CoV-2 proteins form with one another. Related compositions, reaction mixtures, devices, kits, and systems are also provided.

COMPOSITIONS AND METHODS FOR DETECTION AND TREATMENT OF CORONAVIRUS INFECTION

Resumen de: US2025130231A1

The present disclosure includes a multiplexed peptide assay to generate an epitope-resolved view of antibody reactivity across all human coronaviruses (CoVs). PepSeq accurately classifies SARS-CoV-2 exposure status and reveals epitopes across the Spike and Nucleocapsid proteins. Two of these represent recurrent reactivities to conserved, functionally-important sites in the S2 subunit of Spike, regions that we show are also targeted for the endemic CoVs in pre-pandemic controls. At one of these sites, we demonstrate that the SARS-CoV-2 response strongly and recurrently cross-reacts with the endemic virus hCoV-OC43. The disclosed epitope-resolved analysis reveals new CoV targets for the development of diagnostics, vaccines and therapeutics, including a site that may have broad neutralizing potential.

DIAGNOSTIC ASSAY DEVICE HAVING MICROREACTOR

Resumen de: US2025130227A1

Diagnostic assay devices for detecting the presence of an analyte in a sample solution may comprise a microreactor configured to form a sample solution containing the analyte, flow the sample solution therethrough in a first direction to form an analyte-capture molecule complex, and transfer the sample solution to an absorbent strip pad configured to flow therethrough, in a second direction crossing the first direction, the sample solution including the analyte-capture molecule complex and indicate a presence of the analyte-capture molecule complex. The diagnostic devices may be used, for example, to identify the presence of SARS-Cov2, RSV, influenza A, influenza B or other pathogens in samples from patients.

POLYMER FOR INHIBITING SARS-COV-2 AND OTHER PATHOGENS

Resumen de: WO2023242246A1

The present invention relates to methacrylate-based functionalized dendronized polyglycerol polymers. These polymers are highly biocompatible and less anticoagulant, form thread-like single chain fibers and show excellent inhibition against respiratory viruses such as SARS-CoV-2 and HSV-1. They can be easily used for forming degradable hydrogels together with a crosslinker.

SEVERE ACUTE RESPIRATORY SYNDROME (SARS) - ASSOCIATED CORONAVIRUS DIAGNOSTICS

Resumen de: US2021311054A1

The invention relates to the diagnosis of a SARS-associated coronavirus, such as a SARS-CoV-2 infection and SARS-CoV-1 infection, using the N_SARS-COV-1 and N_SARS-CoV-2 proteins and antibodies binding to these proteins. The invention reagents, methods and kits for the detection of a SARS-associated coronavirus.

Method for predicting interaction between RBD in S protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and hACE2 receptor

Resumen de: GB2634804A

A method for predicting an interaction between a receptor-binding domain (RBD) in a spike (S) protein of a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and a human angiotensin-converting enzyme 2 (hACE2) receptor comprises conducting prediction simulation based on a protein structure data and comparing an obtained prediction result with surface plasmon resonance (SPR) experimental data; analysing protein structure simulation and binding simulation based on a sequence data; and analysing protein structure simulation and binding simulation based on a mutation site. The method is based on PROtein binDIng enerGY prediction (PRODIGY) and can predict an interaction mode between the RBD in the S protein and the hACE2 receptor through multiple data types, and can quickly and effectively analyse the infectivity.

Systems and methods for preparing vaccines utilizing predictably inactivated pathogens

Resumen de: GB2634841A

A method is described for producing a vaccine from a neutered pathogenic source. The neutered pathogenic source may be a SARS-COV-2 virus that is neutered with a defined dose of UV-C light. The neutered SARS-COV-2 viral vaccine is administered through an inhalation pump. The architecture of the neutered inactivated virus can be kept intact or partially destroyed by using graded dosage of the UVC.

Broadly SARS-CoV-2 neutralizing monoclonal antibodies and uses thereof

Resumen de: US12281155B1

The invention relates to antibodies against Severe Acute Respiratory Syndrome-related Coronavirus 2 (SARS-CoV-2), in particular human neutralizing monoclonal antibodies against Severe Acute Respiratory Syndrome-related Coronavirus 2 (SARS-CoV-2) having a broad neutralization spectrum, and their use for the diagnosis, monitoring, prevention, and treatment of SARS-CoV-2 infection and associated disease (COVID-19).

COVID-19 Composition for Detecting Biomarker Specific Severity of Covid-19

Resumen de: KR20250052644A

본 발명은 COVID-19 중증도 진단용 바이오마커인 IFNA1 및 IL12p40 검출용 조성물을 제공한다.

METHOD FOR DETERMINING THE LEVEL OF RISK OF SEVERE COVID-19 DISEASE IN A PATIENT

Resumen de: WO2025080149A1

A method for assaying the presence of two genetic polymorphisms whose occurrence significantly modifies the course of COVID-19 disease is disclosed. The genetic polymorphisms, namely rs143334143 locus and at the rs74956615. This method represents a new tool in the public health protection against COVID-19 disease.

KIT AND METHOD FOR DETERMINING BY POLYMERASE CHAIN REACTION THE ALLELE CONFIGURATION AT THE RS143334143 LOCUS AND AT THE RS74956615 LOCUS

Resumen de: WO2025080150A1

The invention relates to a kit comprising a primer pair and optionally probe(s) for assaying the presence of two genetic polymorphisms, namely rs143334143 locus and at the rs74956615 whose occurrence significantly modifies the course of (indicates the risk of a severe) COVID-19 disease. The invention also relates to a method with the same purpose. The kit and the method represent new tools in the public health protection against COVID-19 disease.

VACCINES AGAINST CORONAVIRUS AND METHODS OF USE

Resumen de: US2025121054A1

Disclosed herein are nucleic acid molecules encoding a SARS-CoV-2 spike antigen. SARS-CoV-2 spike antigens, immunogenic compositions, and vaccines and their use in inducing immune responses and protecting against or treating a Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) infection in a subject.

REAL-TIME DISEASE OUTBREAK PHYLOGENETIC ANALYSIS

Resumen de: WO2025081000A1

To infer transmission links using within-host variation, Applicants first developed a statistical model of minor variant frequencies, which Applicants fit to a dataset of 134,682 SARS- CoV-2 genomes from Massachusetts, USA. Applicants then combined this model with a stochastic epidemic process to develop a hierarchical Bayesian statistical model of viral outbreaks. After validating the approach on both synthetic and real outbreak datasets, Applicants applied the tool to 5,692 outbreak clusters among the 134,682 Massachusetts genomes. Applicants found that informative sub-consensus variants are relatively rare in outbreaks, but that when they do occur, they significantly help resolve transmission networks. Applicants methods and results demonstrate the utility of within-host variation for transmission inference of SARS-CoV-2 and other pathogens, stressing the importance of pathogen sequencing in epidemiology and public health.

DYRK/CLK PROTACS AND USES THEREOF

Resumen de: WO2025080753A1

The present invention relates to bifunctional compounds, which find utility to degrade and (inhibit) one or more of the following kinases: DYRK1A, DYRK1B, DYRK2, DYRK3, DYRK4, CLK1, CLK2, CLK3, CLK4, CDK7, CDK8/19, PI3K, PDGFrA/B, mTOR, HIPKs, and/or CMGC kinases leading to inhibition of WNT signaling. In particular, the present invention is directed to compounds, which contain on one end an E3 ubiquitin ligase binding moiety which binds to an E3 ubiquitin ligase and on the other end a moiety which binds one or more of the following kinases: DYRK1A, DYRK1B, DYRK2, DYRK3, DYRK4, CLK1, CLK2, CLK3, CLK4, CDK7, CDK8/19, PI3K, PDGFrA/B, mTOR, HIPKs, and/or CMGC kinases leading to inhibition of WNT signaling, such that the one or more kinases is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of the one or more kinases. The bifunctional compounds serve as therapeutics for the treatment of Alzheimer's disease, down syndrome, diabetes, an autoimmune disease, an inflammatory disorder (e.g., airway inflammation, osteoarthritis (e.g., knee related osteoarthritis)), cancer (e.g., glioblastoma, prostate cancer, metastatic breast cancer, metastatic lung cancer, multiple myeloma, secondary metastatic tumors of the brain, colorectal cancer, acute myeloid leukemia, myelodysplastic syndrome), a viral infection (e.g., SARS-CoV-2 infection (e.g., COVID-19)), and other diseases.

PROTEIN BASED VACCINE AND PRODUCTION METHOD THEREOF FOR SARS COV-2

Resumen de: US2025122243A1

The present invention is directed to a composition, mammalian cell and vector, and a method for the production of, and method of treatment with, a recombinant protein vaccine in a mammalian cell line. The methods and compositions are particularly useful for generating the stable expression of a recombinant protein vaccine of interest. The invention is particularly useful for the production of vaccines to aid in protection against viral pathogens for vertebrates, in particular mammalians, especially humans. The mammalian cell for producing a protein of interest comprises: a plasmid encoded with a nucleotide sequence encoding one or more epitopes or subunits of the SARS-CoV-2 that are embedded in the nucleotide sequence encoding a detoxified recombinant tetanus toxin (DrTeNT).

SARS-COV-2 VACCINES

Resumen de: US2025121052A1

Disclosed herein are vaccine compositions that include SARS-CoV-2 MHC epitope-encoding cassettes and/or full-length SARS-CoV-2 proteins. Also disclosed are nucleotides, cells, and methods associated with the compositions including their use as vaccines.

Protease Inhibitors as Antivirals

Resumen de: US2025122153A1

Provided herein, inter alia, are compounds, pharmaceutical compositions and methods related to the treatment of viral infections caused by coronavirus or enterovirus. Provided herein are compounds of Formula (I), (II) and (III)and methods of using the compounds for therapy. These compounds are peptidomimetics that inhibit protease 3CL of a coronavirus, and are useful for treating conditions caused by viral infections, including COVID-19.

VACCINE COMPOSITIONS AND THEIR USE

Resumen de: US2025121053A1

The invention relates to immunogenic compositions and their use as a vaccine for the prevention of coronavirus disease in a human subject. More specifically, the invention relates to methods of use of an immunogenic composition in the prevention of coronavirus disease in a human subject in need thereof, said immunogenic composition comprising: a fusion protein comprising (i) a SARS-Cov2 nucleocapsid N antigen and, (ii) a carrier protein comprising a self-assembling polypeptide derived from C4bp oligomerization domain and a positively charged tail.

C3D4 Human Cell Model for MERS and SARS-C0V-2 Infection

Resumen de: US2025123269A1

A robust human cell culture model permissive to both SARS-COV-2 variants and MERS-COV is critical for assessment and validation of antivirals. Human alveolar A549 cells are regarded as a valuable model for respiratory virus infection. SARS-COV-2 uses the angiotensin converting enzyme 2 (ACE2) receptor for viral entry and the transmembrane serine protease 2 (TMPRSS2) to prime the SARS-COV-2 spike protein. By contrast, MERS-COV utilizes the dipeptidyl peptidase 4 receptor (DPP4) to enter the target cells. Three of which are negligibly expressed in A549. Disclosed herein is a generation of a robust human cell model that carries DPP4, ACE2, and TMPRSS2 receptor expressions. By transducing Dpp4 into A549-ACE2plusC3 cells (ACE2+/TMPRSS2+), the resulting cells expressing DPP4, ACE2 and TMPRSS2 (“ACE2plusC3D4”) are highly susceptible to MERS-COV and SARS-CoV-2 omicron infection. This ACE2plusC3D4 cell model can be applied for evaluation of antiviral drugs and potentially developed for high-throughput screening.

ALVEOLAR ORGANOIDS, METHODS OF MAKING AND USES THEREOF

Resumen de: US2025123274A1

Methods for obtaining a population of differentiated alveolar cells, differentiated alveolar cells in the form of alveolar organoids generated by the methods and uses for the differentiated alveolar organoids are provided. The methods include digesting long-term expanding lung organoids (LO) into single cells (i.e., dissociated cells), and suspension culturing the dissociated cells in distal differentiation (DD) cell culture media in a non-adherent plate for an effective amount of time. Alveolar organoids includes a population of AT1 and AT2 cells and in suspension culture exhibit an apical-out polarity and include abundant cytoplasmic lamellar bodies and microvilli. The alveolar organoids can be utilized alone or in combination with 2D and 3D AWO, rebuilt the human respiratory epithelium in culture plates for studying biology and pathology of human respiratory system, including, but not limited to, the study of COVID-19 respiratory diseases.

A bacteriophage-based, needle and adjuvant-free, mucosal Covid-19 vaccine

Resumen de: GB2634646A

A bacteriophage T4-based, multivalent/multicomponent, needle and adjuvant-free, mucosal vaccine by engineering spike trimers on capsid exterior and nucleocapsid protein in the interior is disclosed herein. Intranasal administration of this T4-COVID vaccine induces higher virus neutralization antibody titers against multiple variants, balanced Th1/Th2 antibody and cytokine responses, stronger CD4+ and CD8+ T cell immunity, and higher secretory IgA titers in sera and bronchoalveolar lavage with no effect on the gut microbiota, compared to vaccination of mice intramuscularly. The vaccine is stable at ambient temperature, induce apparent sterilizing immunity, and provide complete protection against original SARS-CoV-2 strain and its Delta variant with minimal lung histopathology. This mucosal vaccine is an excellent candidate for boosting immunity of immunized and/or as a second-generation vaccine for the unimmunized population. This needle-free platform could be used to develop effective vaccines against many other respiratory infectious pathogens including Flu and any future emerging epidemic and pandemic pathogens.

METHODS FOR TREATMENT OF VIRAL INFECTIONS INCLUDING SARS-COV-2

Resumen de: AU2023283718A1

The present disclosure relates to methods for treating viral infections in a patient that is not pregnant. Also provided are combination treatments for viral infections in a human in need thereof.

AN ISOLATED POLYPEPTIDE OR ANTIGENIC FRAGMENT THEREOF AND ITS USES FOR DIAGNOSING OR PREDICTING A DISEASE SUCH AS LONG COVID OR POST-VAC-SYNDROME

Resumen de: WO2025073771A1

The present invention inter alia relates to an use of an isolated polypeptide or an antigenic fragment thereof, comprising a polypeptide region having at least 60% sequence identity with any one of the polypeptide sequences selected from the group consisting of SEQ ID No.: 1-11, 16-20 and 23-28; wherein the isolated polypeptide is having a length of no more than 200 contiguous amino acids for diagnosing Long COVID or Post-Vac-Syndrome, or for predicting a risk of developing Long COVID or Post-Vac-Syndrome. The present invention also relates to the isolated polypeptide or antigenic fragment thereof for use in preventing, treating or ameliorating Long COVID or Post-Vac-Syndrome., as well as to a method of detecting a presence of antibodies against SARS-CoV-2 in a subject, comprising the step of contacting a sample of said subject with at least one of the polypeptide or antigenic fragment thereof.

PREDICTING SUSCEPTIBILITY OF LIVING ORGANISMS TO MEDICAL CONDITIONS USING MACHINE LEARNING MODELS

Resumen de: US2025114044A1

Embodiments of the present disclosure generally relate to methods for analyzing outcomes of illnesses, such as COVID-19, on living organisms. More particularly, embodiments of the present disclosure relate to methods for identifying risk of illness based on genetic markers and other available data, predicting results of mass exposure to an Illness based on a populations genomes and other available data, and providing indicators and methods of visualization for probability of illness in any living organism.

NUCLEOSIDES AND NUCLEOTIDES ANALOGS AS ANTIVIRAL AGENTS

Resumen de: US2025114389A1

Compounds, compositions and methods for preventing, treating or curing a coronavirus infection in human subjects or other animal hosts. In one embodiment, the compounds can be used to treat an infection with a severe acute respiratory syndrome virus, such as human coronavirus 229E, SARS, MERS, SARS-CoV-1, OC43, and SARS-CoV-2. In another embodiment, the methods are used to treat a patient infected with a Flavivirus, Picornavus, Togavirus, or Bunyavirus.

COMPOSITIONS INCORPORATING SULFATED POLYSACCHARIDES FOR INHIBITING SARS-COV-2

Resumen de: US2025114394A1

The composition inhibits severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) via competitive binding to SARS-COV-2 spike protein. The composition includes a plurality of sulfated glycosaminoglycans which bind to SARS-COV-2 spike protein, preventing binding to and uptake by host cells. The sulfated glycosaminoglycans, including N-, 2-O, 3-O, or 6-O sulfate groups, or combinations thereof, include heparins and fucoidans, such as those isolated from brown seaweed. The compositions show antiviral activity, with EC50 as low as 0.08 μM, and low cytotoxicity, making it promising for clinical use. While established SARS-COV-2 treatments such as remdesivir need to be administered intravenously, the compositions discussed herein are advantageously capable to being delivered as a nasal spray, metered dose inhaler, oral delivery, etc.

Composition For Treating and Preventing COVID-19 and Method For Treatment of COVID-19

Resumen de: US2025114425A1

A composition for the treatment of or prevention of COVID-19 or long COVID may be a mixture of: water; green tea; lemon juice; red onions; and garlic. One embodiment of the composition may be made by including a plurality of bags of green tea, sliced lemons, lemon juice, cut red onion pieces, and a plurality of cut garlic pieces in water, boiling the composition for about 30 minutes, and then straining the composition. A piece of smashed ginger may be added to the composition prior to boiling. A cup of the composition may be drunk three or more times a day to treat a person having COVID-19, or a cup or more of the composition may be drunk daily to prevent COVID-19.

USE OF BOSWELLIA FOR TREATING SARS-COV-2 INFECTION

Resumen de: US2025114418A1

The present invention relates to the use of extracts from Boswellia species and pharmaceutical compositions comprising Boswellia extracts in the treatment of SARS-CoV-2 infection and related medical conditions.

EXTRACELLULAR VESICLES FOR THERAPY

Resumen de: US2025114445A1

The present disclosure relates to extracellular vesicles comprising one or more antigens from a coronavirus (e.g., SARS-CoV-1 or SARS-CoV-2) and optionally an adjuvant. Also provided herein are methods for producing the EVs and methods for using the EVs to treat and/or prevent diseases or disorders, e.g., infectious diseases.

MULTIPLEXED DIAGNOSTIC ASSAY DEVICE

Resumen de: US2025116668A1

Diagnostic assay devices for detecting the presence of an analyte in a sample solution may comprise a microreactor configured to form a sample solution containing the analyte, flow the sample solution therethrough in a first direction to form an analyte-capture molecule complex, and transfer the sample solution to an absorbent strip pad configured to flow therethrough, in a second direction crossing the first direction, the sample solution including the analyte-capture molecule complex and indicate a presence of the analyte-capture molecule complex. In some embodiments the devices are configured to process a bioaerosol sample. In some embodiments the diagnostic assay devices may be multiplexed and may be used for detecting the presence of two or more analytes in a sample solution. The diagnostic devices may be used, for example, to identify the presence of one or more of SARS-Cov2, RSV, influenza A, influenza B or other pathogens in samples from patients.

METHODS TO DETERMINE CD4+ MEMORY T CELL RESPONSES TO SARS-COV-2 INFECTION OR VACCINATION

Resumen de: US2025116673A1

Disclosed are methods for identifying or determining whether a subject exhibits a CD4+ memory T cell response to SARS-CoV-2 infection or vaccination, assessing the efficacy of a SARS-CoV-2 vaccine, and developing personalized SARS-CoV-2 treatment plans by detecting the presence and/or quantity of a particular T cell receptor a chain that recognizes a specific Spike protein epitope.

CORONAVIRUS SPIKE PROTEIN VARIANTS

Resumen de: WO2025075129A1

Provided are coronavirus spike protein variants for use as antigens for vaccines for coronavirus infections.　The present invention provides coronavirus spike protein variants comprising (a) a receptor binding domain (RBD) formed from the amino acid sequence set forth in SEQ ID NO: 1, (b) an RBD formed from an amino acid sequence in which one to several amino acids have been substituted, deleted, inserted, or added in the amino acid sequence set forth in SEQ ID NO: 1, and having neutralizing antibody-inducing activity against SARS-CoV-2 and SARS-CoV-1 equivalent to RBD formed from the amino acid sequence set forth in SEQ ID NO: 1, or (c) an RBD formed from an amino acid sequence having at least 90% sequence identity with the amino acid sequence set forth in SEQ ID NO: 1, and having neutralizing antibody-inducing activity against SARS-CoV-2 and SARS-CoV-1 equivalent to RBD formed from the amino acid sequence set forth in SEQ ID NO: 1.

SYNTHESIS AND EVALUATION OF 9-AMINOACRIDINES WITH SARS-COV-2 ANTIVIRAL ACTIVITY

Resumen de: WO2025076406A1

The synthesis and characterization of a series of derivatives and analogs based on the 9-aminoacridine scaffold shared by antimalarial drugs quinacrine and pyronaridine are described. Also described is the structure-activity relationship of these compounds against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes the coronavirus disease of 2019 (COVID-19). Several compounds displayed potent in vitro activity, with 50% inhibitory concentrations below 1 micromolar.

EVOLUTION OF FLUOROGENIC SENSORS

Resumen de: AU2023353878A1

Described herein is evolution strategy that leverages highly efficient tRNA charging chemistry for cell-free ribosomal translation of proteins, including fluorogenic sensors. The fluorogenic sensors provided are capable of detecting targets, including antigens such as SARS-CoV-2 variants (

ANTIBODIES CAPABLE OF BINDING TO THE SPIKE PROTEIN OF CORONAVIRUS SARS-COV-2

Resumen de: US2024376178A1

The invention relates to antibodies useful for the prevention, treatment and/or diagnosis of coronavirus infections, and diseases and/or complications associated with coronavirus infections, including COVID-19. In particular, the invention relates to antibodies capable of binding to the spike protein of coronavirus SARS-CoV-2 and uses thereof.

METHODS AND SYSTEMS FOR QUANTITATIVE DETECTION OF SARS-COV-2 ANTIBODIES USING DRIED SAMPLES

Resumen de: US2023393124A1

In certain aspects, disclosed are methods and systems for detecting SARS-CoV-2 analytes in dried samples, as for example, dried blood spots. For example, disclosed are methods for measuring an antibody to SARS-CoV-2 in a dried sample that include the steps of: (a) obtaining a dried sample from a subject; (b) extracting the SARS-COV-2 antibody from the dried sample; and (c) detecting the SARS-COV-2 antibody extracted from the dried sample. In certain embodiments, the method is semi-quantitative. The method may, in certain embodiments, further comprise obtaining measurements from an individual over a period of time to follow the titer of SARS-CoV-2 antibody in the individual. For example, the titer may be followed in the individual for at least 19 weeks or longer.

LIVE-ATTENUATED SARS-COV-2 VACCINE

Resumen de: WO2023235863A1

Engineered SARS-CoV-2 variants having a combination of attenuating modifications, and their use as live-attenuated SARS-CoV-2 vaccines, are described. The recombinant genome of the live-attenuated SARS-CoV-2 encodes a modified spike (S) protein with a deletion of the polybasic site (DPRRA); encodes a modified non-structural protein 1 (Nsp1) with K164A and H165A substitutions; and includes a mutation that prevents expression of open reading frames (ORFs) 6, 7a, 7b and 8. The disclosed live-attenuated SARS-CoV-2 retain the capacity to infect and replicate in mammalian cells. Immunogenic compositions that include a live-attenuated SARS-CoV-2 and methods of eliciting an immune response against SARS-CoV-2 in a subject are also described. Further disclosed are a collection of reverse genetics plasmids that include the complement of the recombinant genome of the live-attenuated SARS-CoV-2 and methods of producing a live-attenuated SARS-CoV-2 using the reverse genetics plasmids.

MULTIVALENT COVID-19 VACCINES BASED ON ADENOVIRAL VECTORS

Resumen de: AU2023276011A1

The present invention relates to the construction of Adenovirus-based vectors und to their use for inducing a broad, robust and durable cellular and humoral immune response in a subject.

DIAGNOSTIC TESTING APPARATUS AND SYSTEM

Resumen de: AU2023334598A1

A method and an apparatus utilizing targeted ion mobility spectrometry for the detection of the SARS-CoV-2 virus and its variants, by measuring the quantity of free polyamines including putrescine, spermidine, and spermine in a sublingual saliva sample. Other embodiments are capable of providing instant, cost effective, POC testing and test results for other viral and bacterial infections including influenza, acute and chronic respiratory conditions, certain forms of inflammation, and the detection of certain abnormal cells in human subjects.

ANTIVIRAL SIRNA THERAPEUTIC FOR SARS-COV-2

Resumen de: AU2023347083A1

This disclosure relates to RNA interference (RNAi) reagents for treatment of SARS-CoV-2 infection, compositions comprising same, and use thereof to treat or prevent infection by SARS- CoV-2.

ANTI-SARS-COV-2 SPIKE (S) ANTIBODIES AND THEIR USE IN TREATING COVID-19

Resumen de: WO2025072888A2

The present invention provides antibodies that bind to the SARS-CoV-2 Spike (S) protein. The invention further relates to pharmaceutical compositions, immunotherapeutic compositions, and methods using the aforementioned antibodies that bind to the SARS-CoV-2 Spike (S) protein.

VALACYCLOVIR AND CELECOXIB FOR THE TREATMENT OF ALZHEIMER'S DISEASE AND COVID-19

Resumen de: AU2023341167A1

The present disclosure relates to methods of treating Alzheimer's disease, diseases and/or conditions associated with Covid-19 infection, including long COVID, a post-acute infection syndrome, or symptoms of orthostatic intolerance comprising administration of a therapeutically-effective combination of a COX-2 inhibitor and an antiviral compound.

TREATMENT USING A ONE-TO-STOP ATTENUATED SARS-COV-2 VIRUS

Resumen de: AU2023361023A1

The invention relates to pharmaceutical product comprising a polynucleotide for use in the prevention or treatment of a SARS-CoV-2 virus infection wherein said SARS-CoV-2 virus is not a Wuhan wild-type SARS-CoV-2 virus. The polynucleotide encodes an attenuated human coronavirus or a fragment thereof, wherein the polynucleotide comprises at least 20 one-to-stop codons, wherein a one-to-stop codon is i) a different but synonymous codon compared to the corresponding codon in a natural human coronavirus genome and ii) differs by one nucleotide from a STOP codon.

METHODS AND SYSTEMS FOR RAPID DETECTION OF COVID-19

Resumen de: US2025110112A1

Methods for diagnosing a subject for a COVID-19 infection state include collecting an alveolar air breath sample from a subject; passing the breath sample into contact with a volatile organic compound (VOC) sensor operable to detect a plurality of VOC biomarkers for a COVID-19 infection state; producing a readable sensor output for at least two of the plurality of biomarkers; and diagnosing the COVID-19 infection state of the subject based on the readable sensor output. Systems for detecting and identifying at least one VOC biomarker for a COVID-19 infection state in exhaled breath of a subject include a mouth piece connected to a housing, the mouth piece operable to receive the exhaled breath of the subject; a sensor module disposed in the housing, the sensor module operable to detect the at least one VOC biomarker in the exhaled breath, and further operable to produce a readable sensor output for the at least one VOC biomarker; and a communication module disposed in the housing and in communication with the sensor module, the communication module operable to transmit collected data from the sensor module.

HYBRID FLU-CORONAVIRUS VACCINE

Resumen de: US2025108108A1

A hybrid vaccine composition that prevents infection or reinfection by both influenza and coronaviruses, comprising at least a portion of a Coronavirus spike(S) protein and at least a portion of at least one influenza hemagglutinin (HA) protein. The portion of the coronavirus spike(S) protein is highly conserved among human and animal coronaviruses. The vaccine composition may comprise a Coronavirus protein comprising either: a structural protein, e.g., a Spike protein, a Nucleocapsid protein, or a combination thereof, or a non-structural protein, e.g., NSP2, NSP3, NSP14, or combination thereof; and at least a portion of at least one influenza hemagglutinin (HA) protein.

VACCINES AND RELATED METHODS

Resumen de: US2025108107A1

Provided herein are SARS-CoV-2 spike proteins and polypeptides (e.g., SARS-CoV-2 spike proteins and polypeptide immunogens (and immunogenic fragments and immunogenic variants thereof)) comprising at least one set of amino acid substitutions, and nucleic acid molecules encoding the same. Further provided herein are compositions (e.g., pharmaceutical compositions) and vaccines comprising the same for use in e.g., the prevention, treatment, and/or amelioration of a SARS-CoV-2 infection.

NANOENCAPSULATED PHARMACEUTICAL COMPOSITION AND USE THEREOF

Resumen de: US2025108106A1

This disclosure is directed to a pharmaceutical composition for treating or preventing a disease. The pharmaceutical composition can comprise a polymer-drug nanoaggregate having a polymer and at least one bioactive agent that can comprise STING polypeptide, a nucleic acid encoding said STING polypeptide, a STING inhibitor, a STING activator, a STING agonist, a STING antagonist, a STING modulating molecule, or a combination thereof. The pharmaceutical composition can be a vaccine or an adjuvant for a vaccine. This disclosure is also directed to a method for treating or preventing a disease using the pharmaceutical composition. The disease can include infectious diseases caused by viruses or other pathogens, for example, influenza, rabies, or respiratory illnesses such as severe acute respiratory syndrome (SARS) caused by coronaviruses, such as MERS-CoV, SARS-CoV, and Coronavirus Disease 2019 (COVID-19) caused by the virus SARS-CoV-2 and its variants.

RECOMBINANT POLYPEPTIDES CONTAINING AT LEAST ONE IMMUNOGENIC FRAGMENT AND ANTIBODY FC REGION AND USES THEREOF

Resumen de: US2025109173A1

Provided is a recombinant polypeptide containing at least one immunogenic fragment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2) spike glycoprotein, and pharmaceutical compositions containing the same.

CHIMERIC PROTEIN PRODUCTION PROCESS, CHIMERIC PROTEIN, GENE, IMMUNOGENIC COMPOSITION AND USES

Resumen de: US2025109421A1

The production process for a chimeric protein with SEQ ID No. 1, using the nucleotide sequence with SEQ ID No. 2; the chimeric protein defined by SEQ ID No. 1, the gene in SEQ ID No. 2 used for its production, immunogenic compositions containing the protein, and the use thereof to prepare vaccines for prophylaxis and prevention of infection and moderate and severe forms of COVID-19. The present technology falls within the field of human health, specifically in the field of preventive measures against infection with SARS-CoV2. It involves the production of a vaccine composition comprising a chimeric protein that prevents high viral loads and moderate and severe clinical forms of the disease by stimulating the immune system.

ANTI-SARS-COV-2 VIRUS PROTEIN OR MRNA VACCINE, PREPARATION METHOD THEREFOR, AND USE THEREOF

Resumen de: WO2025067013A1

An anti-SARS-CoV-2 virus protein or mRNA vaccine, a preparation method therefor, and a use thereof. The protein has one or more amino acid residues added, deleted, or replaced in the amino acid sequence as shown in SEQ ID NO: 18. The nucleic acid encodes an S protein mutant. Preclinical animal test data shows that the mRNA vaccine has a good protective effect for the current variants of concern (VOC) of the SARS-CoV-2 virus and has broad clinical application prospects.

3CL-PROTEASE INHIBITORS FOR TREATING OR PREVENTING VETERINARY CORONAVIRUS INFECTIONS

Resumen de: WO2025067202A1

Provided herein are methods for treating or preventing a disease caused by veterinary coronavirus in a non-human animal suffering from coronavirus infection, in particular, feline coronavirus infection.

SARS-CoV-2 BINDING PROTEINS AND METHODS OF USE THEREOF

Resumen de: US2025109186A1

Certain embodiments of the invention provide isolated anti-SARS-CoV-2 sdAbs, as well as polypeptides and protein molecules comprising such sdAbs. Certain embodiments of the invention also provide methods of using these sdAbs, polypeptides and protein molecules for treating or preventing a SARS-CoV-2 infection.

ANTI-SARS-CoV-2 SPIKE (S) ANTIBODIES AND THEIR USE IN TREATING COVID-19

Resumen de: US2025109187A1

The present invention provides antibodies that bind to the SARS-CoV-2 Spike (S) protein. The invention further relates to pharmaceutical compositions, immunotherapeutic compositions, and methods using the aforementioned antibodies that bind to the SARS-CoV-2 Spike (S) protein.

T cell receptor sequences diagnostic for COVID-19 and related compositions

Resumen de: US12266425B1

Provided are methods of assessing a biological sample obtained from an individual for the presence of a T cell that expresses a T cell receptor (TCR) comprising a TCRβ CDR3 sequence set forth in Table 1. Such methods further comprise identifying the individual as having COVID-19 when the presence of the TCR is detected. The presence of one or more of these TCRs may be of use in prognosticating severity of COVID-19 in the individual and the individual may be treated based on the expected severity of COVID-19. Treatment methods may include administering to the individual a T cell engineered to express the TCR. Such engineered T cells are also disclosed. Also provided are compositions and multimers that find use, e.g., in practicing the methods of the present disclosure.

Sars-cov-2 immunogenic compositions and methods

Resumen de: AU2023329395A1

The present disclosure relates to compositions and methods for vaccinating a subject against multiple SARS-CoV-2 variants that involves the making and delivery of extracellular vesicles expressing on their surface engineered spike protein and/or engineered nucleocapsid protein to the subject. The present invention also relates to compositions and methods for the design, preparation, manufacture, formulation, and/or use of spike-display and nucleocapsid-display vesicular vaccines designed to elicit strong humoral and cellular immune responses against multiple SARS-CoV-2 variants.

A live attenuated sars-cov-2 and a vaccine made thereof

Resumen de: AU2023336178A1

The invention relates to a polynucleotide encoding a) severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein; and/or b) at least one non-structural SARS-CoV-2 protein selected from the group consisting of non-structural protein 7, non-structural protein 8, non-structural protein 9, non-structural protein 10, non-structural protein 11, non-structural protein 12, an endoribonuclease, and a 2'-O-methyltransferase, wherein the polynucleotide comprises or consists of at least one sequence part comprising codon-pair deoptimizations in comparison to the SARS-CoV-2 genome, and wherein the polynucleotide further comprises a furin cleavage site modification resulting in a loss of a furin cleavage site being naturally present in the SARS-CoV-2 genome. The invention further relates to a live attenuated SARS- CoV-2 comprising this polynucleotide, to a vaccine comprising this live attenuated SARS-CoV-2, as well as to associated methods.

COVID-19 Methods for Predicting Severity and Monitoring progress of COVID-19

Resumen de: KR20230153844A

The present invention relates to a biomarker for predicting or diagnosing COVID-19 severity, use thereof, a method for screening candidate substances for preventing, treating, or alleviating COVID-19, a biomarker for predicting or monitoring the progress of COVID-19, and use thereof. According to the present invention, the biomarker can accurately determine whether COVID-19 severity is present and can clearly determine the condition of a lesion and whether a patient improves after treatment. A biomarker composition for predicting or diagnosing COVID-19 severity comprises at least one selected from a group consisting of NEAT1, MALAT1, and combinations thereof, or a gene encoding the same.

ANTIBODIES CAPABLE OF BINDING TO THE SPIKE PROTEIN OF CORONAVIRUS SARS-COV-2

Resumen de: US2024376178A1

The invention relates to antibodies useful for the prevention, treatment and/or diagnosis of coronavirus infections, and diseases and/or complications associated with coronavirus infections, including COVID-19. In particular, the invention relates to antibodies capable of binding to the spike protein of coronavirus SARS-CoV-2 and uses thereof.

HUMAN ANTI-SARS-COV-2 SPIKE (S) ANTIBODIES

Resumen de: WO2025064752A1

The present invention includes a monoclonal antibody or antigen-binding fragment thereof, methods of using, detection, recombinant vectors, host cells, kits, variants, and pharmaceutical compositions that include the antibody or antigen-binding fragment thereof that binds to the S2 domain of the SARS-CoV-2 Spike protein.

SYNTHETIC COMPOUNDS COMPRISING DIHYDROISOQUINOLINONE MONOMERS

Resumen de: WO2025064641A1

Embodiments are directed to dihydroisoquinolinone (Dhq) monomers and synthetic compounds comprises at least Dhq monomer having the structure (I). In such embodiments, X is selected from C and N and each R1 and R2 are independently selected from H, O, phenyl, allyl, alkenyl, carbonyl, and a combination thereof. In some embodiments, the synthetic compounds can bind to a spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or to fentanyl.

SMALL MOLECULE INHIBITORS OF GPCR GPR68 AND RELATED RECEPTORS FOR TREATING CANCER, GLIOBLASTOMA, AND OTHER INDICATIONS

Resumen de: US2025099438A1

The invention relates to a class of small molecule inhibitors of GPR68/OGR1, a proton-sensing/stretch-sensing/sheer-stress-sending G-protein coupled receptor, and related receptors GPR4 and GPR65. These inhibitors are useful as a therapeutic for glioblastoma and other neoplasms, as a monotherapy or adjuvant, and also can be used as a treatment for other conditions, such as osteoporosis, inflammatory bowel disease, autoimmune and chronic inflammatory diseases such as multiple sclerosis and inflammatory pain syndromes, GERD, aspiration pneumonitis, bacterial and viral pneumonia, COPD, acute respiratory distress syndrome (ARDS), and COVID-19.

5-FLUOROURACIL AS AN ANTIVIRAL AGENT AGAINST VIRUSES OF THE FAMILY CORONAVIRIDAE

Resumen de: WO2025062057A1

The present invention relates to 5-fluorouracil (5-FU) for use thereof as an antiviral, alone or in combination with peptides that inhibit binding between nsp10 and nsp14 and between nsp10 and nsp16, acting against viruses of the family Coronaviridae, preferably SARS-CoV-2.

Nitrile-Containing Antiviral Compounds

Resumen de: US2025099424A1

The invention relates to compounds of Formula I″wherein R, R1, R2, R3, p, q and q′ are as defined herein, pharmaceutical compositions comprising the compounds, methods of treating coronavirus infection such as COVID-19 in a patient by administering therapeutically effective amounts of the compounds, and methods of inhibiting or preventing replication of coronaviruses such as SARS-CoV-2 with the compounds.

Recombinant RNA Molecules Comprising Untranslated Regions or Segments Encoding Spike Protein from the Omicron Strain of Severe Acute Respiratory Coronavirus-2

Resumen de: US2025099576A1

Provided herein are 3′ and 5′ UTRs that provide an amount, duration, or both of protein expression from a recombinant RNA. Compositions of matter, methods, or uses of said 3′ and 5′ UTRs are provided. Provided herein are RNA segments that encode a SARS-CoV-2 omicron spike protein, which provide for omicron-strain-specific immunogenic compositions. Compositions of matter, methods, or uses of said RNA segments that encode a SARS-CoV-2 omicron spike protein are provided.

SYSTEM AND METHOD FOR PREDICTING DEPRESSION DURING THE COVID-19 PANDEMIC USING INTERPRETABLE AI AND PROGRAM STORED IN A RECORDING MEDIUM

Resumen de: KR20250042454A

본 발명의 일 실시예에 의하면, 해석가능한 인공지능을 이용한 우울 장애 예측 시스템이 제공될 수 있다. 우울 장애 예측 시스템은, 우울 장애 확률을 예측하기 위한 복수의 설명 변수 및 결과 변수에 대한 데이터를 포함하는 샘플 데이터를 수집하는 샘플 데이터 수집부; 분석 대상자의 우울 장애 확률을 예측하기 위한 복수의 학습 모델을 구축하고, 샘플 데이터를 이용하여 복수의 학습 모델에 대한 학습을 수행하는 학습 수행부; 구축된 복수의 학습 모델로부터 성능 통계에 기초하여 결과 변수에 영향을 미치는 설명 변수의 서브 세트를 구성하고, 각 서브 세트에 대한 복수의 학습 모델의 성능 통계에 기초하여 어느 하나의 설명 변수의 서브 세트를 선택하는 변수 선택부; 수집된 샘플 데이터의 선택된 설명 변수 및 결과 변수에 의해 복수의 학습 모델에 대한 학습을 수행하고, 각 학습 모델에 대한 성능 통계에 기초하여 분석 대상자의 우울 장애 확률을 예측하기 위한 하나의 학습 모델을 선택하는 학습 모델 선택부; SHAP(SHapley Additive exPlanations)을 이용하여 우울 장애 예측과 관련한 각 설명 변수의 영향도를 제공하는 영향도 산출부를 포함할 수 있다.

SARS-COV-2 S PROTEIN POLYPEPTIDE ANTIGEN AND APPLICATION THEREOF

Resumen de: US2025099573A1

Provided are a polypeptide antigen derived from the S protein of SARS-CoV-2, a polypeptide vaccine containing the same, and applications thereof. The amino acid sequence of the polypeptide antigen provided by the present disclosure is as shown in any one of SEQ ID NOs: 1-116.

COMPOSITIONS AND METHODS FOR USING PURIFIED HUMAN RNA EDITING ENZYMES

Resumen de: US2025101427A1

In alternative embodiments, provided are methods for eradicating or reducing the in vivo numbers of cancer stem cells comprising administering to an individual in need thereof an ADAR1 (adenosine deaminase associated with RNA1) inhibiting agent, wherein the ADAR1 inhibiting agent reduces, or significantly reduces, ADAR1 Nano-luc reporter activity in cell lines and in human cancer stem cell assays. In alternative embodiments, provided are methods for inhibiting an RNA virus or a retrovirus, optionally a SARs-COV-2 virus, comprising lentiviral ADAR1 overexpression and in vivo administration, optionally intravenous (IV) administration, of a lentiviral ADAR1 transduced stem cell, optionally the stem cell is a cord blood CD34+ cell or a mesenchymal stromal cell.

HUMAN NEUTRALIZING ANTIBODY AGAINST SARS-COV-2 HAVING BREADTH TO VARIANT STRAINS, AND ANTIGEN-BINDING FRAGMENT THEREOF

Resumen de: US2025101085A1

In order to provide a novel human-derived monoclonal antibody that binds to a spike (S) protein of a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to neutralize SARS-CoV-2, an antigen-binding fragment thereof, and a pharmaceutical composition containing the antibody or the antigen-binding fragment thereof, the present invention provides: a human-derived monoclonal antibody against SARS-CoV-2, the antibody binding to the S protein of SARS-CoV-2 to neutralize viral activity of the S protein including an immune escape mutation; an antigen-binding fragment thereof; nucleic acids encoding the antibody and the antigen-binding fragment thereof; and a pharmaceutical composition for treating or preventing a SARS-CoV-2 coronavirus infectious disease, the pharmaceutical composition containing the antibody or the antigen-binding fragment thereof.

VACCINE COMPOSITIONS

Resumen de: US2025099572A1

The invention relates to vaccine compositions for inducing an immune response to a coronavirus in a subject, and uses thereof. In particular, the vaccine comprises of a chimeric or fusion protein comprising a) a N-terminal secretion signal peptide; b) an amino acid sequence of the receptor binding domain (RBD) of a spike protein of a coronavirus; and c) a C-terminal domain comprising a transmembrane region and a cytoplasmic region. In a preferred embodiment, the signal peptide, RBD, transmembrane region, and cytoplasmic region are derived from SARS-CoV-2, and that the vaccine composition is formulated as a lipid nanoparticle (LNP).

COMPOUND FOR USE IN PREVENTING AND/OR TREATING AN INFECTION CAUSED BY SARS-COV-2

Resumen de: US2025099530A1

The present invention relates to the field of the treatment and/or prevention of viral infection caused by SARS-CoV-2. The inventor found that N-(2(quinolyl)-valyl-O-methylaspartyl-(2,6-difluorophenoxy)methyl ketone was able to inhibit SARS-CoV-2 replication both in vitro and in vivo and that this inhibition was more important compared to the one obtained with the non-O-methylated form of this compound (quinolyl-valyl-aspartyl--2,6-difluorophenoxy-methyl ketone). Thus the present invention concerns the N-(2(quinolyl)-valyl-O-methylaspartyl-(2,6-difluorophenoxy)methyl ketone or a pharmaceutically acceptable salt or solvate thereof for use in preventing and/or treating a viral infection caused by SARS-CoV-2. The present invention also concerns a pharmaceutical composition and a kit of parts comprising such a compound for the same use.

PHARMACEUTICAL FOR TREATMENT OF NOVEL CORONAVIRUS INFECTION

Resumen de: US2025099474A1

The present invention provides a pharmaceutical composition containing a coronavirus 3CL protease inhibitor for treating novel coronavirus infections (COVID-19).A pharmaceutical composition for treating novel coronavirus infections (COVID-19) is provided, the composition containing, as an active ingredient, a complex that contains:a compound represented by Formula (I):andfumaric acid.

Methods of Treating a Subject for Long-Haul COVID-19, and Compositions for Use in the Same

Resumen de: US2025099444A1

Methods of treating a subject for long-haul COVID are provided. Aspects of the methods include administering to the subject a tropane CCR5/CCL5 interaction inhibitor in combination with a statin to treat the subject for long-haul COVID. Also provided are compositions for use in practicing the methods.

GLYCEROPHOSPHOINOSITOL IN PREVENTING AND TREATING COVID-19 INFECTIONS AND METHOD FOR OBTAINING IT

Resumen de: WO2023223189A1

The present invention relates to the use of glycerophosphoinositol (GPI) in preventing and treating COVID-19 infections, and an environmentally sustainable method for obtaining it. In particular, the present invention is directed to a process for preparing glycerophosphoinositol from crude or partially purified phospholipid mixtures, comprising the following steps in sequence: a) hydrolysis of a crude or partially purified phospholipid mixture by treatment with PLA1 and PLA2 enzymes; b) microfiltration of the mixture from step a) and subsequent ultrafiltration and nanofiltration of the microfiltrate to give a concentrated aqueous fraction of reaction products; c) electrodialysis of the aqueous fraction of step b) for separating ionic compounds from neutral compounds; d) ion exchange chromatography. The invention further relates to the use of glycerophosphoinositol in preventing and treating a COVID-19 syndrome.

BOVINE COLOSTRUM DERIVED ANTIBODIES AND USES THEREOF

Resumen de: ZA202309295B

A method to produce immunoglobulin preparations against viral infection in humans spreading via respiratory route is provided. The method comprises the steps of immunizing dairy cows during a third trimester of at least a first gestation period with antigen proteins derived from at least one virus strain, collecting hyperimmune bovine colostrum comprising immunoglobulins effective against the antigen protein of various strains of the virus, preparing whey from the colostrum, isolating the immunoglobulin molecules from the whey, and preparing an immunoglobulin preparation for use as an intranasal treatment. One aspect of the invention is to produce SARS-CoV-2 spike protein specific hyperimmune bovine colostrum comprising a high concentration of anti-SARS-CoV-2 antibodies. An intranasal delivery system for diminishing risk of SARS-CoV-2 infections in humans is provided.

Detection of optimal recombinants using fluorescent protein fusions

Resumen de: GB2634002A

A method for producing a SARS-CoV-2 virus-like particle-based protein subunit vaccine. The method comprises creating a fusion protein by combining a DNA sequence encoding an iLOV protein with a DNA sequence encoding a peptide linker and a cleavage site for enterokinase protease and a DNA sequence encoding a Receptor Binding Domain (RBD) of the SARS-CoV-2 viral spike protein. The RBD protein is attached to a “Spy Tag” peptide. The peptide linker cleavage site DNA sequence is between the iLOV protein DNA sequence and either the SARS-CoV-2 viral protein DNA sequence or the “Spy Tag” peptide DNA sequence. The DNA sequence encoding the fusion protein is introduced into a P. pastoris host to form transformants. At least one optimal recombinant is identified from the transformants using fluorescence to detect optimal expression levels of the SARS-CoV-2 viral protein. The SARS-CoV-2 viral protein is isolated from the fusion protein by cleaving the iLOV protein and linker sequences from the target protein. The RBD sequence can be mutated to represent RBD variants or homologous sequences or improve expression and alter its glycosylation pattern. The RBD sequence can belong to any virus within the coronavirus family.

METHODS AND KITS FOR DIAGNOSING COVID-19 DISEASE

Nº publicación: ZA202309817B 26/03/2025

Solicitante:

UNIV STELLENBOSCH [ZA]
STELLENBOSCH UNIVERSITY

Resumen de: ZA202309817B

This invention relates to methods of diagnosing COVID-19 disease, preferably post-acute COVID-19 syndrome, in a subject using a fluorescent or microscopy detection method to detect persistent anomalous (amyloid) clotlets in the sample, wherein the presence of persistent anomalous (or amyloid) clotlets in the sample, particularly clotlets that are resistant to fibrinolysis, is indicative of either acute COVID-19 disease or post-acute COVID-19 syndrome in the subject. The invention also relates to diagnostic kits for diagnosing acute COVID-19 disease, in particular post-acute COVID-19 syndrome, in a subject based on the methods disclosed.